NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生物製藥合同製造市場:第 4 版

Biopharmaceutical Contract Manufacturing Market (4th Edition) by Type of Product (API, FDF), Scale of Operations (Preclinical, Clinical and Commercial), Expression System (Mammalian, Microbial and Others), Company Size

出版商 Roots Analysis 商品編碼 1008220
出版日期 內容資訊 英文 783 Pages
商品交期: 最快1-2個工作天內
價格
生物製藥合同製造市場:第 4 版 Biopharmaceutical Contract Manufacturing Market (4th Edition) by Type of Product (API, FDF), Scale of Operations (Preclinical, Clinical and Commercial), Expression System (Mammalian, Microbial and Others), Company Size
出版日期: 2021年02月28日內容資訊: 英文 783 Pages
簡介

多年來,生物製藥的日益普及帶來了醫學範式的轉變。僅在過去十年中,美國 FDA 每年批准的生物製藥數量就穩步增加。鑑於生物製藥相對於小分子藥物具有明顯的優勢,包括高效、靶向特異性和良好的安全性,未來幾年生物製藥市場將持續穩定增長。生物製藥製造是一個帶來挑戰的複雜、資本密集型的□□過程。

本報告調查和分析了生物製藥合同製造市場,重點關註生物製藥 CMO 和合同製造組織 (CDMO) 的多種職能,並系統地描述了當前的市場狀況和未來的機會。

目錄

第 1章前言

第 2 章執行摘要

第 3 章介紹

第 4 章競爭形勢

  • 章節概述
  • 生物製藥合同製造商:整體市場形勢

第 5 章生物製藥承包機構 (CMO) 製造設施

  • 章節概述
  • 主要先決條件和技術
  • 生物製藥合同生產設施總體情況
  • 北美生物製藥合同製造工廠
  • 歐洲生物製藥合同製造工廠
  • 亞太地區生物製藥合同製造工廠

第 6 章北美生物製藥合同製造

  • 章節概述
  • 美國生物製藥合同製造:監管情景
  • 北美主要生物製藥 CMO
    • AGC Biologics
    • Catalent (Catalent Pharma Solutions)
    • Cytiva (GE Healthcare)
    • FUJIFILM Diosynth Biotechnologies
    • KBI Biopharma
    • Patheon (acquired by Thermo Fisher Scientific)
    • Piramal Pharma Solutions

第 7 章歐洲生物製藥合同製造

  • 章節概述
  • 歐洲生物製藥合同製造:監管情景
  • 歐洲主要生物製藥 CMO
    • Boehringer Ingelheim BioXcellence
    • Lonza
    • Novasep
    • Olon
    • Rentschler Biopharma
    • Sandoz

第 8 章亞太及其他地區生物製藥合同製造

  • 章節概述
  • 中國生物製藥合同製造
  • 中國主要生物製藥 CMO
  • 印度生物製藥合同製造
  • 印度主要生物製藥 CMO
  • 日本生物製藥合同製造
  • 日本主要生物製藥 CMO
  • 韓國生物製藥合同製造
  • 韓國主要生物製藥 CMO
  • 澳大利亞生物製藥合同製造
  • 澳大利亞主要生物製藥 CMO

第 9 章利基生物製藥事業部

  • 章節概述
  • 雙特異性抗體
  • 抗體藥物偶聯物 (ADC)
  • 細胞療法
  • 基因治療
  • 質粒 DNA

第 10 章案例研究:生物仿製藥外包

  • 章節概述
  • 生物類似藥:介紹
  • 生物類似藥:開發階段
  • 生物類似藥許可的監管要求
  • 需要外包生物仿製藥的開發和製造
  • 生物仿製藥對全球合同製造市場的影響
  • 生物仿製藥合同製造服務商
  • 與生物仿製藥生產業務外包相關的問題

第 11 章案例研究:小藥和高分子藥物/治療的比較

  • 章節概述
  • 小分子/高分子藥物/治療

第 12 章案例研究:內部製造

  • 章節概述
  • 內部製造
  • 生物製藥行業的外包
  • 用於經批准的生物製藥的製造方法
  • 選擇正確的策略:內部製造與外包

第 13 章製造與採購決策框架

第 14 章各大藥企的舉措

第 15 章夥伴關係和協作

第 16 章併購

第 17 章最近的擴展

第 18 章最新進展

第 19 章容量分析

  • 章節概述
  • 主要先決條件和技術
  • 生物製藥 CMO:全球產能
  • 結論

第 20 章需求分析

  • 章節概述
  • 主要先決條件和技術
  • 生物製藥市場的總體年度需求
  • 年需求量與產能的關係
  • 對新興生物製藥的需求
  • 全球對細胞療法製造的需求

第 21 章市場規模和機會規模

  • 章節概述
  • 主要先決條件和技術
  • 全球生物製藥合同製造市場
  • 生物製藥合同製造市場分佈:按使用的表達系統類型
  • 生物製藥合同製造市場分佈:按經營規模
  • 生物製藥合同製造市場分佈:按公司規模
  • 生物製藥合同製造市場-分佈:按製造的生物製藥類型
  • 生物製藥合同製造市場-分佈:按地區

第 22 章SWOT分析

第 23 章生物製藥 CMO 市場的未來

第 24 章調查分析

第 25 章採訪

第 26 章附錄1:表格數據

第 27 章附錄 2:公司/組織名單

目錄

Title:
Biopharmaceutical Contract Manufacturing Market (4th Edition)
by Type of Product (API, FDF), Scale of Operations (Preclinical, Clinical and Commercial), Expression System (Mammalian, Microbial and Others), Company Size (Small, Mid-sized, Large and Very Large), Biologics (Antibody, Vaccine, Cell Therapy and Other Biologics) and Key Geographical Regions (North America, Europe, Asia-Pacific, MENA and LATAM)- Industry Trends and Global Forecast to 2030.

Overview:

“ The development pipelines of big biopharma companies are extensive and it is difficult for such players to carry out manufacturing operations using in house capacities. As a result, such companies often opt to outsource certain aspects of their production processes, predominantly drug substance manufacturing and aseptic filling. Therefore, there is a high demand for contract services from the aforementioned companies. ” - Senior Manager Strategic Marketing, a Germany-based Large sized CMO.

Over the years, the rising popularity of biologics has led to a paradigm shift in healthcare. In the last decade alone, the annual number of approvals of biopharmaceuticals, by the US FDA, have steadily risen. In fact, in 2019, a total of 28 biopharmaceutical products (including monoclonal antibodies, recombinant proteins and gene therapies) were approved in the US. Further, over 8,000 biological pharmaceutical products are currently under clinical investigation, across the world. Given the evident benefits (including high efficacy, target specificity and favorable safety profiles) of biologics over small molecule drugs, the biopharma market is poised to witness continued and consistent growth over the next several years. However, biologics production is a complex and capital-intensive process fraught with a wide range of challenges. Some of key concerns of contemporary innovators include the rate of attrition of pipeline drugs / therapies, prolonged development timelines, complex molecular structure (which demand niche and specialized expertise), current facility limitations and capacity constraints, and safety and efficacy-related issues.

Given the technical and operational challenges outlined above, an increasing number of drug developers have demonstrated the preference to outsource various parts of their biologics manufacturing operations. The landscape of contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) market, specifically those that claim to have biologics-related capabilities, features a mix of large, mid-sized and small companies. As a result of several mergers and acquisitions, the market is now fairly consolidated with a number of established players operating as one-stop-shops. Moreover, since the biopharmaceutical sector is amongst the most highly regulated industries in the world, biopharma CMOs, specifically those offering regulatory assistance, are perceived as attractive strategic partners (especially to the smaller developer companies). With outsourcing being increasingly accepted as a viable and beneficial business model within the biopharmaceutical industry, we anticipate the biologics manufacturing services market to grow at a steady pace in the coming years.

Scope of the Report:

The "Biopharmaceutical Contract Manufacturing Market (4th Edition) by Type of Product (API, FDF), Scale of Operations (Preclinical, Clinical and Commercial), Expression System (Mammalian, Microbial and Others), Company Size (Small, Mid-sized, Large and Very Large), Biologics (Antibody, Vaccine, Cell Therapy and Other Biologics) and Key Geographical Regions (North America, Europe, Asia-Pacific, MENA and LATAM)- Industry Trends and Global Forecast to 2030" report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analyses, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and contract development and manufacturing organizations (CDMOs). Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring an elaborate list of active CMOs, along with information on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), scale of operation (preclinical, clinical and commercial), types of expression systems used (mammalian, microbial and others), type of bioreactor used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion), bioprocessing capacity and type of packaging.
  • A detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), and including an analysis based on the location of these facilities, highlighting key manufacturing hubs for biologics.
  • Elaborate profiles of key players that claim to have a diverse range of capabilities related to the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as an informed future outlook.
  • A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
  • A case study on the growing global biosimilars market, highlighting the associated opportunities for biopharmaceutical CMOs and CDMOs.
  • A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
  • A detailed discussion on the benefits and challenges associated with in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource the production operations.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A review of the various biopharmaceutical based manufacturing initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation, types of biologics manufactured and type of product.
  • An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of biologics, based on various parameters, such as the year the agreement was signed, type of agreement, focus area, types of biologics manufactured, therapeutic area and geographical regions.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired during 2015-2020, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples (based on revenues), number of employees and experience of the acquired company.
  • A detailed analysis of the recent expansions undertaken (since 2015) by various service providers for augmenting their respective biopharma contract manufacturing service portfolios, based on a number of parameters, including year of expansion, purpose of expansion (capacity expansion and new facility), types of biologics manufactured, geographical location of facility, and most active players (in terms of number of instances).
  • An analysis of the recent developments within the biopharmaceutical contract manufacturing industry, highlighting information on the funding and technology advancements related to biomanufacturing.
  • A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small, mid-sized, large and very large CMOs / CDMOs) engaged in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), company size (small, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, South Korea and Australia), Latin America, Middle East and North Africa).
  • An informed estimate of the annual demand for biologics, taking into account the top 25 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
  • A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to biopharmaceutical developers.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs), finished dosage formulations (FDFs)), [B] types of expression systems used (mammalian, microbial and others), [C] scale of operation (preclinical, clinical and commercial), [D] company size (small, mid-sized and large / very large), [E] types of biologics manufactured (antibody, vaccine, cell therapy and other biologics) and [F] key geographical regions (North America (the US, Canada), Europe (the UK, France, Germany, Italy and Spain), Asia (China, India and Australia), Latin America, Middle East and North Africa). To account for the uncertainties associated with the manufacturing of biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders (arranged in alphabetical order):

  • Andrea Conforto (Sales & Marketing, Bioservices Director, Olon)
  • Astrid Brammer (Senior Manager Business Development, Richter-Helm)
  • Birgit Schwab (Senior Market Intelligence Manager, Rentschler Biotechnologie)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Claire Otjes (Marketing Manager, Batavia Biosciences)
  • David C Cunningham (Director Corporate Development, Goodwin Biotechnology)
  • Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
  • Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
  • Kevin Daley (Market Director Pharmaceuticals, Novasep)
  • Mark Wright (ex-Site Head, Grangemouth, Piramal Healthcare)
  • Max Rossetto (General Manager - Business Development, Luina Bio)
  • Nicolas Grandchamp (R&D Leader, GEG Tech)
  • Raquel Fortunato (Chief Executive Officer, GenIbet Biopharmaceuticals)
  • Sebastian Schuck (Director Global Business Development, WACKER BIOTECH Biotech)
  • Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies)
  • Marco Schmeer (Project Manager, PlasmidFactory) and Tatjana Buchholz (ex-Marketing Manager, PlasmidFactory)
  • Tim Oldham (ex - Chief Executive Officer, Cell Therapies)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the biopharmaceutical contract manufacturing market in the mid to long term.

Chapter 3 provides a general introduction to biopharmaceuticals and biopharmaceutical manufacturing processes. The chapter also includes an overview of the various expression systems used for the development of different types of biotherapeutic products. It features a brief overview of contract manufacturing, along with a detailed discussion on the need for outsourcing within the biopharmaceutical industry. We have also presented a list of commonly outsourced biomanufacturing activities. The chapter concludes with a discussion on the challenges faced by players currently engaged in the market.

Chapter 4 provides a detailed overview of the global biopharmaceutical contract manufacturing landscape. It includes information related to over 200 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as such as year of establishment, company size, location of headquarters of the CMO, type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), scale of operation (preclinical, clinical and commercial), types of expression systems used (mammalian, microbial and others), type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion), bioprocessing capacity and type of packaging.

Chapter 5 provides a detailed landscape of biopharmaceutical manufacturing facilities in key regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa). It includes analysis and map representations based on location of these facilities, highlighting key provinces as the manufacturing hubs.

Chapter 6 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in the North America. Each profile presents a brief overview of the company, its contract service offerings, financial information (if available), information related to manufacturing facilities, partnerships, recent developments (expansions) and an informed future outlook.

Chapter 7 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Europe. Each profile presents a brief overview of the company, its contract service offerings, financial information (if available), information related to manufacturing facilities, partnerships, recent developments (expansions) and an informed future outlook.

Chapter 8 features detailed profiles of some of the key players that are active in the biopharmaceutical contract manufacturing market in Asia and other regions of the world. Each profile presents a brief overview of the company, its contract service offerings, financial information (if available), information related to manufacturing facilities, partnerships, recent developments (expansions) and an informed future outlook.

Chapter 9 focuses on the key enablers in this domain, including certain niche product classes, such as ADCs, bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market. The chapter provides detailed a market overview, including information on the pipeline, and the presence of CMOs in each of the aforementioned segments.

Chapter 10 is a case study focused on outsourcing of operations associated with biosimilars, which represents a major growth opportunity for biopharmaceutical CMOs. It provides an overview of biosimilars and captures information on the various CMOs that are actively involved in this segment of the biopharmaceutical market.

Chapter 11 is a case study comparing the key characteristics of small and large molecule drugs, along with information on the steps involved in their respective manufacturing processes.

Chapter 12 is a case study focused on challenges associated with in-house manufacturing. It also provides details on the outsourcing trends in this domain, along with information related to various partnership models that are being used by various stakeholders to partner with CMOs. In addition, it features a list of recently approved biologics, with information on the type of biologic, target indication(s), developer and manufacturing approach adopted by the developer. Further, the chapter features a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource its operations.

Chapter 13 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of CMOs.

Chapter 14 provides a detailed analysis of biopharmaceutical based manufacturing related initiatives of the big pharma players (shortlisted on the basis of the revenues generated by the top 10 pharmaceutical companies in 2019), featuring trends across various parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation, types of biologics manufactured and type of product.

Chapter 15 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players since 2015. It includes a brief description on the various types of partnership models (which include product-based agreements, process-based agreements, licensing agreements, co-service agreements / ventures, R&D agreements and other outsourcing service agreements) that have been adopted by stakeholders in this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the manufacturing of biologics. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 16 includes a detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired from 2015-2020. The analysis also provides information on the key value drivers for these mergers and acquisitions and the corresponding acquisition deal multiples.

Chapter 17 presents an analysis of the recent expansions undertaken (since 2015) by various service providers for augmenting their respective biopharma contract manufacturing service portfolios, based on a number of parameters, including year of expansion, purpose of expansion (capacity expansion and new facility), types of biologics manufactured, geographical location of facility, and most active players (in terms of number of instances).

Chapter 18 provides details on the funding instances and emerging technologies related to biomanufacturing processes.

Chapter 19 features a comprehensive analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of biopharmaceutical products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of the company (small, mid-sized, large and very large), region of operation (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia-Pacific (China, India, Japan, South Korea and Australia), Latin America, Middle East and North Africa).

Chapter 20 features a comprehensive analysis of the annual demand of biotherapeutics (in grams), taking into account the top 25 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.

Chapter 21 presents a comprehensive market forecast analysis, highlighting the likely growth of the biologics manufacturing market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] commonly outsourced business operations (active pharmaceutical ingredients (APIs), finished dosage formulations (FDFs), [B] expression system used (mammalian, microbial and others), [C] scale of operation (preclinical, clinical and commercial), [D] company size (small, mid-sized and large / very large), [E] types of biologics manufactured (antibody, vaccine, cell therapy and other biologics) and [F] key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy and Spain), Asia (China India and Australia), Latin America, Middle East and North Africa.

Chapter 22 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of biopharmaceuticals manufacturing market, under a comprehensive SWOT framework.

Chapter 23 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the biopharmaceutical CMOs market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of biopharmaceutical CMOs.

Chapter 24 presents insights from the survey conducted for this study. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 25 contains the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the biopharmaceutical contract manufacturing domain. In this study, we spoke to (in alphabetical order) Andrea Conforto (Sales and Marketing, Bioservices Dierector, Olon), Astrid Brammer (Senior Manager Business Development, Richter-Helm), Birgit Schwab (Senior Market Intelligence Manager, Rentschler Biotechnologie), Christian Bailly (Director of CDMO, Pierre Fabre), Claire Otjes (Marketing Manager, Batavia Biosciences), David C Cunningham (Director Corporate Development, Goodwin Biotechnology), Dietmar Katinger (Chief Executive Officer, Polymun Scientific), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences), Kevin Daley (Market Director Pharmaceuticals, Novasep), Mark Wright (ex-Site Head, Grangemouth, Piramal Healthcare), Max Rossetto (General Manager - Business Development, Luina Bio), Nicolas Grandchamp (R&D Leader, GEG Tech), Raquel Fortunato (Chief Executive Officer, GenIbet Biopharmaceuticals), Sebastian Schuck (Director Global Business Development, Wacker Biotech Biotech), Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies), Marco Schmeer (Project Manager, PlasmidFactory) and Tatjana Buchholz (ex-Marketing Manager, PlasmidFactory) and Tim Oldham (ex-Chief Executive Officer, Cell Therapies).

Chapter 26 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 27 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Biopharmaceuticals
  • 3.3. Expression Systems for Biopharmaceuticals
    • 3.3.1. Insect Expression Systems
    • 3.3.2. Mammalian Expression Systems
    • 3.3.3. Microbial Expression Systems
      • 3.3.3.1. Bacterial Expression Systems
      • 3.3.3.2. Fungal Expression Systems
      • 3.3.3.3. Yeast Expression Systems
    • 3.3.4. Plant Expression Systems
    • 3.3.5. Mammalian versus Microbial Expression Systems
  • 3.4. Manufacturing Process of Biopharmaceuticals
    • 3.4.1. Upstream Processing
    • 3.4.2. Fermentation
    • 3.4.3. Downstream Processing
  • 3.5. Overview of Contract Manufacturing
  • 3.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
    • 3.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
    • 3.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
    • 3.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
  • 3.7. Key Considerations while Selecting a Contract Manufacturing Partner
  • 3.8. Future Perspectives

4. COMPETITIVE LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Type of Product
    • 4.2.5. Analysis by Types of Biologics Manufactured
    • 4.2.6. Analysis by Scale of Operation
    • 4.2.7. Analysis by Types of Expression Systems Used
    • 4.2.8. Analysis by Type of Bioreactors
    • 4.2.9. Analysis by Mode of Operation of Bioreactors

5. MANUFACTURING FACILITIES OF BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS (CMOs)

  • 5.1. Chapter Overview
  • 5.2. Key Assumptions and Methodology
  • 5.3. Overall Landscape of Biopharmaceutical Contract Manufacturing Facilities
    • 5.3.1. Analysis by Type of Product
    • 5.3.2. Analysis by Scale of Operation
    • 5.3.3. Analysis by Type of Expression System Used
  • 5.4. Biopharmaceutical Contract Manufacturing Facilities in North America
  • 5.5. Biopharmaceutical Contract Manufacturing Facilities in Europe
  • 5.6. Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific

6. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

  • 6.1. Chapter Overview
  • 6.2. Biopharmaceutical Contract Manufacturing in the US: Regulatory Scenario
    • 6.2.1. Impact of Current Political Situation
  • 6.3. Leading Biopharmaceutical CMOs in North America
    • 6.3.1. AGC Biologics
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Service Portfolio
        • 6.3.1.2.1. Process Development
        • 6.3.1.2.2. cGMP Manufacturing
        • 6.3.1.2.3. Quality and Regulatory
        • 6.3.1.2.4. Process Validation
      • 6.3.1.3. Financial Information
      • 6.3.1.4. Manufacturing Facilities
      • 6.3.1.5. Partnerships
      • 6.3.1.6. Recent Developments
      • 6.3.1.7. Future Outlook
    • 6.3.2. Catalent (Catalent Pharma Solutions)
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Service Portfolio
        • 6.3.2.2.1. Cell Line Development
        • 6.3.2.2.2. Manufacturing (Biomanufacturing)
        • 6.3.2.2.3. ADCs and Bioconjugates Manufacturing
        • 6.3.2.2.4. Biosimilars Development and Manufacturing
        • 6.3.2.2.5. Proprietary Delivery and Fill / Finish Solutions
        • 6.3.2.2.6. Analytical Services
      • 6.3.2.3. Clinical Supply Services
      • 6.3.2.4. Financial Information
      • 6.3.2.5. Manufacturing Facilities
      • 6.3.2.6. Partnerships
      • 6.3.2.7. Recent Developments
      • 6.3.2.8. Future Outlook
    • 6.3.3. Cytiva (GE Healthcare)
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Service Portfolio
        • 6.3.3.2.1. Biomanufacturing Services
        • 6.3.3.2.2. Scientific Support
        • 6.3.3.2.3. OptiRun Service Solutions
        • 6.3.3.2.4. Instruments Qualification Services
      • 6.3.3.3. Financial Information
      • 6.3.3.4. Manufacturing Facilities
      • 6.3.3.5. Partnerships
      • 6.3.3.6. Recent Developments
      • 6.3.3.7. Future Outlook
    • 6.3.4. FUJIFILM Diosynth Biotechnologies
      • 6.3.4.1. Company Overview
      • 6.3.4.2. Service Portfolio
        • 6.3.4.2.1. Strain Development
        • 6.3.4.2.2. Process Development
        • 6.3.4.2.3. GMP Contract Manufacturing
        • 6.3.4.2.4. Analytical Solutions
      • 6.3.4.3. Financial Information
      • 6.3.4.4. Manufacturing Facilities
      • 6.3.4.5. Partnerships
      • 6.3.4.6. Recent Developments
      • 6.3.4.7. Future Outlook
    • 6.3.5. KBI Biopharma
      • 6.3.5.1. Company Overview
      • 6.3.5.2. Service Portfolio
        • 6.3.5.2.1. Process Development
        • 6.3.5.2.2. Analytical Development
        • 6.3.5.2.3. GMP Manufacturing
        • 6.3.5.2.4. Clinical Cell Therapy Support
      • 6.3.5.3. Manufacturing Facilities
      • 6.3.5.4. Partnerships
      • 6.3.5.5. Future Outlook
    • 6.3.6. Patheon (acquired by Thermo Fisher Scientific)
      • 6.3.6.1 Company Overview
      • 6.3.6.2. Service Portfolio
        • 6.3.6.2.1. Biologics
          • 6.3.6.2.1.1. Drug Substance
        • 6.3.6.2.2. Analytical Services
        • 6.3.6.2.3. Product Development
        • 6.3.6.2.4. Commercial Product Supply
      • 6.3.6.3. Financial Information
      • 6.3.6.4. Manufacturing Facilities
      • 6.3.6.5. Partnerships
      • 6.3.6.6. Recent Developments
      • 6.3.6.7. Future Outlook
    • 6.3.7. Piramal Pharma Solutions
      • 6.3.7.1 Company Overview
      • 6.3.7.2. Service Portfolio
        • 6.3.7.2.1. Antibody Drug Conjugation Services
        • 6.3.7.2.2. Other Services
      • 6.3.7.3. Financial Information
      • 6.3.7.4. Manufacturing Facilities
      • 6.3.7.5. Future Outlook

7. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

  • 7.1. Chapter Overview
  • 7.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
    • 7.2.1. EMA's cGMP Regulations
  • 7.3. Leading Biopharmaceutical CMOs in Europe
    • 7.3.1. Boehringer Ingelheim BioXcellence
      • 7.3.1.1. Company Overview
      • 7.3.1.2. Service Portfolio
        • 7.3.1.2.1. Process Development
          • 7.3.1.2.1.1. Expression Systems
          • 7.3.1.2.1.2. Upstream Technology
          • 7.3.1.2.1.3. Downstream Technology
          • 7.3.1.2.1.4. Other Process Development Services
        • 7.3.1.2.2. Quality Assurance
        • 7.3.1.2.3. Fill / Finish
      • 7.3.1.3. Financial Information
      • 7.3.1.4. Manufacturing Facilities
      • 7.3.1.5. Partnerships
      • 7.3.1.6. Recent Developments
      • 7.3.1.7. Future Outlook
    • 7.3.2. Lonza
      • 7.3.2.1. Company Overview
      • 7.3.2.2. Service Portfolio
      • 7.3.2.3. Manufacturing Services
      • 7.3.2.4. Financial Information
      • 7.3.2.5. Manufacturing Facilities
      • 7.3.2.6. Partnerships
      • 7.3.2.7. Recent Developments
      • 7.3.2.8. Future Outlook
    • 7.3.3. Novasep
      • 7.3.3.1 Company Overview
      • 7.3.3.2. Service Portfolio
        • 7.3.3.2.1. Services for Viruses and Viral Vectors
        • 7.3.3.2.2. Services for Monoclonal Antibodies
        • 7.3.3.2.3. Services for ADCs
        • 7.3.3.2.4. Quality, Regulatory and Other Services
      • 7.3.3.3. Financial Information
      • 7.3.3.4. Manufacturing Facilities
      • 7.3.3.5. Partnerships
      • 7.3.3.6. Recent Developments
      • 7.3.3.7. Future Outlook
    • 7.3.4. Olon
      • 7.3.4.1. Company Overview
      • 7.3.4.2. Service Portfolio
      • 7.3.4.3. Manufacturing Facilities
      • 7.3.4.4. Future Outlook
    • 7.3.5. Rentschler Biopharma
      • 7.3.5.1. Company Overview
      • 7.3.5.2. Service Portfolio
        • 7.3.5.2.1. Bioprocess Development
        • 7.3.5.2.2. Biomanufacturing Services
        • 7.3.5.2.3. Other Services
      • 7.3.5.3. Manufacturing Facilities
      • 7.3.5.4. Partnerships
      • 7.3.5.5. Recent Developments
      • 7.3.5.6. Future Outlook
    • 7.3.6. Sandoz
      • 7.3.6.1. Company Overview
      • 7.3.6.2. Service Portfolio
      • 7.3.6.3. Financial Information
      • 7.3.6.4. Future Outlook

8. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND THE REST OF THE WORLD

  • 8.1. Chapter Overview
  • 8.2. Biopharmaceutical Contract Manufacturing in China
    • 8.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
    • 8.2.2. Challenges Faced while Outsourcing to China
  • 8.3. Leading Biopharmaceutical CMOs in China
    • 8.3.1. WuXi AppTec (WuXi Biologics)
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Service Portfolio
        • 8.3.1.2.1. Discovery Services
        • 8.3.1.2.2. Development Services
        • 8.3.1.2.3. Testing Services
        • 8.3.1.2.4. Clinical Manufacturing Services
        • 8.3.1.2.5. Fill / Finish Operations
      • 8.3.1.3. Financial Information
      • 8.3.1.4. Manufacturing Facilities
      • 8.3.1.5. Partnerships
      • 8.3.1.6. Recent Developments
      • 8.3.1.7. Future Outlook
  • 8.4. Biopharmaceutical Contract Manufacturing in India
    • 8.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
    • 8.4.2. Challenges Faced while Outsourcing to India
  • 8.5. Leading Biopharmaceutical CMOs in India
    • 8.5.1. Kemwell Biopharma
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Service Portfolio
        • 8.5.1.2.1. Development Services for Biopharmaceuticals
        • 8.5.1.2.2. Manufacturing Services for Biopharmaceuticals
      • 8.5.1.3. Manufacturing Facilities
      • 8.5.1.4. Partnerships
      • 8.5.1.5. Recent Developments
      • 8.5.1.6. Future Outlook
  • 8.6. Biopharmaceutical Contract Manufacturing in Japan
    • 8.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario
  • 8.7. Leading Biopharmaceutical CMOs in Japan
    • 8.7.1. Minaris Regenerative Medicine
      • 8.7.1.1. Company Overview
      • 8.7.1.2. Service Portfolio
        • 8.7.1.2.1. Manufacturing Development
        • 8.7.1.2.2. GMP Manufacturing
      • 8.7.1.3. Manufacturing Facilities
      • 8.7.1.4. Recent Developments
      • 8.7.1.5. Future Outlook
    • 8.7.2. Takara Bio
      • 8.7.2.1. Company Overview
      • 8.7.2.2. Service Portfolio
      • 8.7.2.3. Financial Information
      • 8.7.2.4. Manufacturing Facilities
      • 8.7.2.5. Future Outlook
  • 8.8. Biopharmaceutical Contract Manufacturing in South Korea
    • 8.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
  • 8.9. Leading Biopharmaceutical CMOs in South Korea
    • 8.9.1. Celltrion
      • 8.9.1.1. Company Overview
      • 8.9.1.2. Service Portfolio
      • 8.9.1.3. Financial Information
      • 8.9.1.4. Manufacturing Facilities
      • 8.9.1.5. Future Outlook
    • 8.9.2. Samsung BioLogics
      • 8.9.2.1. Company Overview
      • 8.9.2.2. Service Portfolio
        • 8.9.2.2.1. Process Development
        • 8.9.2.2.2. Analytical Services
        • 8.9.2.2.3. cGMP Manufacturing Services
        • 8.9.2.2.4. Aseptic Fill / Finish
        • 8.9.2.2.5. Quality Services
        • 8.9.2.2.6. Other Services
      • 8.9.2.3. Financial Information
      • 8.9.2.4. Manufacturing Facilities
      • 8.9.2.5. Partnerships
      • 8.9.2.6. Recent Developments
      • 8.9.2.7. Future Outlook
  • 8.10. Biopharmaceutical Contract Manufacturing in Australia
    • 8.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
  • 8.11. Leading Biopharmaceutical CMOs in Australia
    • 8.11.1. Cell Therapies
      • 8.11.1.1. Company Overview
      • 8.11.1.2. Service Portfolio
      • 8.11.1.3. Manufacturing Facilities
      • 8.11.1.4. Partnerships
      • 8.11.1.5. Future Outlook
    • 8.11.2. Luina Bio
      • 8.11.2.1. Company Overview
      • 8.11.2.2. Service Portfolio
        • 8.11.2.2.1. Microbial Products
        • 8.11.2.2.2. Vaccines
        • 8.11.2.2.3. Support Services
        • 8.11.2.2.4. Quality-related Services
      • 8.11.2.3. Manufacturing Facilities
      • 8.11.2.4. Partnerships
      • 8.11.2.5. Recent Developments
      • 8.11.2.6. Future Outlook

9. NICHE BIOPHARMACEUTICAL SECTORS

  • 9.1. Chapter Overview
  • 9.2. Bispecific Antibodies
    • 9.2.1. Introduction
    • 9.2.2. Pipeline Analysis
      • 9.2.2.1. Bispecific Antibody Therapeutics: Clinical Pipeline
      • 9.2.2.2. Bispecific Antibody Therapeutics: Early Stage Pipeline
      • 9.2.2.3. Multivalent Drug Candidates
    • 9.2.3. Analysis by Phase of Development
    • 9.2.4. Analysis by Target Indication
    • 9.2.5. Bispecific Antibody Therapeutics: List of Technology Providers
    • 9.2.6. Key Manufacturing Considerations and Challenges
    • 9.2.7. Contract Manufacturing Scenario
      • 9.2.7.1. CMOs Offering Services for Bispecific Antibodies
  • 9.3. Antibody Drug Conjugates (ADCs)
    • 9.3.1. Components of ADCs
      • 9.3.1.1. Antibody
      • 9.3.1.2. Cytotoxin
      • 9.3.1.3. Linker
    • 9.3.2. Manufacturing Process
    • 9.3.3. Pipeline Analysis
      • 9.3.3.1. ADC Therapeutics: Clinical Pipeline
    • 9.3.4. Analysis by Phase of Development
    • 9.3.5. Analysis by Target Indication
    • 9.3.6. Key Technology Players: Analysis by Number of ADC Therapeutics
    • 9.3.7. Novel Drug Conjugates
    • 9.3.8. Key Manufacturing Considerations and Challenges
    • 9.3.9. Contract Manufacturing Scenario
      • 9.3.9.1. CMOs Offering Services for ADCs
  • 9.4. Cell Therapies
    • 9.4.1. Introduction
    • 9.4.2. Current Market Landscape
    • 9.4.3. Cell Therapy Manufacturing
      • 9.4.3.1. Cell Therapy Manufacturing Models
        • 9.4.3.1.1. Centralized Manufacturing
        • 9.4.3.1.2. Decentralized Manufacturing
    • 9.4.4. Key Manufacturing Considerations and Challenges
    • 9.4.5. Factors Influencing Cell Therapy Manufacturing
      • 9.4.5.1. Characterization
      • 9.4.5.2. Cost of Goods
      • 9.4.5.3. Automation of Cell Therapy Manufacturing
    • 9.4.6. Analysis by Types of Cells Manufactured
    • 9.4.7. Stem Cell Therapies: Analysis by Phase of Development
    • 9.4.8. T-Cell Therapies: Analysis by Phase of Development
    • 9.4.9. Contract Manufacturing Scenario
      • 9.4.9.1. CMOs Offering Services for Cell Therapy
  • 9.5. Gene Therapy
    • 9.5.1. Gene Therapy Market: Pipeline Analysis
      • 9.5.1.1. Analysis by Stage of Development
      • 9.5.1.2. Analysis by Phase of Development
      • 9.5.1.3. Analysis by Type of Vector Used
        • 9.5.1.3.1. Clinical Pipeline
        • 9.5.1.3.2. Preclinical Pipeline
      • 9.5.1.4. Analysis by Target Indication
        • 9.5.1.4.1. Clinical and Commercial Pipeline
        • 9.5.1.4.1. Preclinical Pipeline
      • 9.5.1.5. Analysis by Location of Manufacturing Facility
      • 9.5.1.6 Analysis by Type of Viral Vector Used
    • 9.5.2. Contract Manufacturing Scenario
      • 9.5.2.1. CMOs Offering Services for Viral Vectors
  • 9.6. Plasmid DNA
    • 9.6.1. Introduction
    • 9.6.2. Analysis by Location of Manufacturing Facility
    • 9.6.3. Contract Manufacturing Scenario
      • 9.6.3.1. CMOs Offering Services for Plasmid DNA

10. CASE STUDY: OUTSOURCING OF BIOSIMILARS

  • 10.1. Chapter Overview
  • 10.2. Biosimilars: An Introduction
  • 10.3. Biosimilars: Development Stages
  • 10.4. Regulatory Requirements for Licensing of Biosimilars
  • 10.5. Need for Outsourcing Biosimilar Development and Manufacturing
  • 10.6. Impact of Biosimilars on the Global Contract Manufacturing Market
    • 10.6.1. Pipeline Analysis of Biosimilars, 2013 versus 2020
  • 10.7. Biosimilars Contract Manufacturing Service Providers
  • 10.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations

11. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES

  • 11.1. Chapter Overview
  • 11.2. Small Molecule and Large Molecule Drugs / Therapies
    • 11.2.1. Comparison of General Characteristics
    • 11.2.2. Comparison of Key Specifications
    • 11.2.3. Comparison of Manufacturing Process
    • 11.2.4. Comparison of Key Manufacturing Challenges

12. CASE STUDY: IN-HOUSE MANUFACTURING

  • 12.1. Chapter Overview
  • 12.2. In-House Manufacturing
    • 12.2.1. Benefits Associated with In-House Manufacturing
    • 12.2.2. Risks Associated with In-House Manufacturing
  • 12.3. Outsourcing in the Biopharmaceutical Industry
    • 12.3.1. Types of Outsourcing Partners
  • 12.4. Manufacturing Approaches Used for Approved Biologics (2016-2020)
    • 12.4.1. Approved Biologics: Analysis by Company Size and Type of Manufacturing Model Adopted
    • 12.4.2. Approved Biologics: Analysis by Company Size and Types of Biologics
  • 12.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

  • 13.1. Chapter Overview
  • 13.2. Assumptions and Key Parameters
  • 13.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
    • 13.3.1. Scenario 1
    • 13.3.2. Scenario 2
    • 13.3.3. Scenario 3
    • 13.3.4. Scenario 4
  • 13.4. Conclusion

14. BIG PHARMA INITIATIVES

  • 14.1. Chapter Overview
  • 14.2. List of Biopharmaceutical Manufacturing Initiatives of Big Pharma Players
    • 14.2.1. Analysis by Number of Initiatives
    • 14.2.2. Analysis by Year of Initiative
    • 14.2.3. Analysis by Purpose of Initiative
    • 14.2.4. Analysis by Type of Initiative
      • 14.2.4.1. Analysis by Type of Partnership
      • 14.2.4.2. Analysis by Type of Expansion
    • 14.2.5. Analysis by Scale of Operation
    • 14.2.6. Analysis by Types of Biologics Manufactured
    • 14.2.7. Analysis by Year of Initiative and Company
    • 14.2.8. Analysis by Purpose of Initiative and Company
    • 14.2.9. Analysis by Year and Type of Initiative
    • 14.2.10. Analysis by Type of Region of Expansion and Company
    • 14.2.11 Analysis by Types of Biologics Manufactured and Company
  • 14.3. Competitive Benchmarking of Big Pharma Players
    • 14.3.1. Harvey Ball Analysis: Big Pharma Investment Summary

15. PARTNERSHIPS AND COLLABORATIONS

  • 15.1. Chapter Overview
  • 15.2. Partnership Models
  • 15.3. Biopharmaceutical Contract Manufacturing: List of Collaborations
    • 15.3.1. Analysis by Year of Partnership
    • 15.3.2. Analysis by Type of Partnership
    • 15.3.3. Analysis by Focus Area
    • 15.3.4. Analysis by Focus Area and Type of Partnership Model Adopted
    • 15.3.5. Analysis by Year and Type of Partnership Model Adopted
    • 15.3.6. Analysis by Types of Biologics Manufactured
    • 15.3.7. Analysis by Year and Types of Biologics Manufactured
    • 15.3.8. Analysis by Types of Biologics Manufactured and Type of Partnership Model Adopted
    • 15.3.9. Analysis by Types of Biologics Manufactured and Geography
    • 15.3.10. Analysis by Therapeutic Area
    • 15.3.11. Most Active Players: Analysis by Number of Partnerships
    • 15.3.12. Regional Analysis
    • 15.3.13. Local and Intracontinental Agreements

16. MERGERS AND ACQUISITIONS

  • 16.1. Chapter Overview
  • 16.2. Merger and Acquisition Models
  • 16.3. Acquisition Models
  • 16.4. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
    • 16.4.1. Cumulative Year-wise Trend
    • 16.4.2. Analysis by Type of Acquisition
    • 16.4.3. Analysis by Geographical Activity
      • 16.4.3.1. Mergers and Acquisitions: Continent-wise Distribution
      • 16.4.3.2. Mergers and Acquisitions: Country-wise Distribution
    • 16.4.4. Mergers and Acquisitions: Intercontinental and Intracontinental Deals
    • 16.4.5. Most Active Acquirers: Analysis by Number of Acquisitions
    • 16.4.6 Analysis by Key Value Drivers
      • 16.2.6.1. Analysis by Key Value Drivers and Year of Acquisition
      • 16.2.6.2. Analysis by Key Value Drivers and Types of Biologics Manufactured
      • 16.2.6.3. Analysis by Types of Biologics Manufactured
  • 16.3. Key Acquisitions: Deal Multiples

17. RECENT EXPANSIONS

  • 17.1. Chapter Overview
  • 17.2. Biopharmaceutical Contract Manufacturing Market: Expansions
    • 17.2.1. Cumulative Year-wise Distribution
    • 17.2.2. Analysis by Purpose of Facility Expansion
    • 17.2.3. Analysis by Year and Purpose of Expansion
    • 17.2.4. Analysis by Types of Biologics Manufactured
    • 17.2.5. Analysis by Types of Biologics Manufactured and Purpose of Expansion
    • 17.2.6. Analysis by Location of Manufacturing Facility
    • 17.2.7. Regional Analysis
    • 17.2.8. Most Active Players: Analysis by Number of Recent Expansions
    • 17.2.9. Analysis by Location of Headquarters and Purpose of Expansion
    • 17.2.10. Facility Expansions: 2016-2018 and 2016-2020 Scenario

18. RECENT DEVELOPMENTS

  • 18.1. Biopharmaceutical Contract Manufacturing Market: Funding Instances
  • 18.2. Technological Advancements
    • 18.2.1. Single Use Technology
    • 18.2.2. Process Analytical Technology (PAT)
    • 18.2.3. Continuous Processing
    • 18.2.4. Quality by Design (QbD) in Bio-Processing
    • 18.2.5. Modular / Podular Biopharma Facilities

19. CAPACITY ANALYSIS

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Biopharmaceutical CMOs: Global Production Capacity
    • 19.3.1. Analysis by Company Size
    • 19.3.2. Analysis by Type of Expression Systems Used
    • 19.3.3. Analysis by Scale of Operation
    • 19.3.4. Analysis by Region
      • 19.3.4.1. Capacity Analysis: North America
      • 19.3.4.2. Capacity Analysis: Europe
      • 19.3.4.3. Capacity Analysis: Asia-Pacific
  • 19.4. Conclusion

20. DEMAND ANALYSIS

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. Overall Annual Demand for Biopharmaceuticals Market, 2020-2030
    • 20.3.1. Analysis by Therapeutic Area
  • 20.4. Relationship Between Annual Demand and Capacity
  • 20.5. Demand for Emerging Novel Biologics
    • 20.5.1. ADC Therapeutics: Overall Annual Demand
    • 20.5.2. ADC Therapeutics: Demand and Supply Analysis
  • 20.6. Global Demand for Cell Therapy Manufacturing

21. MARKET SIZING AND OPPORTUNITY SIZING

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Global Biopharmaceutical Contract Manufacturing Market, 2020-2030
    • 21.3.1. Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2020-2030
    • 21.3.2. Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2020-2030
    • 21.3.3. Biopharmaceutical Contract Manufacturing Market for Others Manufacturing, 2020-2030
  • 21.4. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Type of Expression Systems Used
  • 21.5. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
  • 21.6. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Company Size
  • 21.7. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Biologics Manufactured
  • 21.8. Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Geography
    • 21.8.1. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030
      • 21.8.1.1. Biopharmaceutical Contract Manufacturing Market in the US, 2020-2030
      • 21.8.1.2. Biopharmaceutical Contract Manufacturing Market in Canada, 2020-2030
      • 21.8.1.3. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations
      • 21.8.1.4. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations
      • 21.8.1.5. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations
      • 21.8.1.6. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations
      • 21.8.1.7. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Operations
      • 21.8.1.8. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies
      • 21.8.1.9. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
      • 21.8.1.10. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
      • 21.8.1.11. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Antibody Therapeutics
      • 21.8.1.12. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Vaccines
      • 21.8.1.13. Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Cell Therapies
    • 21.8.2. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030
      • 21.8.2.1. Biopharmaceutical Contract Manufacturing Market in Italy, 2020-2030
      • 21.8.2.2. Biopharmaceutical Contract Manufacturing Market in Germany, 2020-2030
      • 21.8.2.3. Biopharmaceutical Contract Manufacturing Market in France, 2020-2030
      • 21.8.2.4. Biopharmaceutical Contract Manufacturing Market in Spain, 2020-2030
      • 21.8.2.5. Biopharmaceutical Contract Manufacturing Market in the UK, 2020-2030
      • 21.8.2.6. Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2020-2030
      • 21.8.2.7. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations
      • 21.8.2.8. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations
      • 21.8.2.9. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations
      • 21.8.2.10. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations
      • 21.8.2.11. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations
      • 21.8.2.12. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies
      • 21.8.2.13. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
      • 21.8.2.14. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
      • 21.8.2.15. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Antibody Therapeutics
      • 21.8.2.16. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Vaccines
      • 21.8.2.17. Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Cell Therapies
    • 21.8.3. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030
      • 21.8.3.1. Biopharmaceutical Contract Manufacturing Market in China, 2020-2030
      • 21.8.3.2. Biopharmaceutical Contract Manufacturing Market in India, 2020-2030
      • 21.8.3.3. Biopharmaceutical Contract Manufacturing Market in South Korea, 2020-2030
      • 21.8.3.4. Biopharmaceutical Contract Manufacturing Market in Japan, 2020-2030
      • 21.8.3.5. Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030
      • 21.8.3.6. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mammalian Cell-based Operations
      • 21.8.3.7. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Microbial Cell-based Operations
      • 21.8.3.8. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Other Expression System-based Operations
      • 21.8.3.9. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Preclinical / Clinical Operations
      • 21.8.3.10. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Commercial Scale Operations
      • 21.8.3.11. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Small Companies
      • 21.8.3.12. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mid-sized Companies
      • 21.8.3.13. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Large / Very Large Companies
      • 21.8.3.14. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Antibody Therapeutics
      • 21.8.3.15. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Vaccines
      • 21.8.3.16. Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Cell Therapies
    • 21.8.4. Biopharmaceutical Contract Manufacturing Market in Latin America, 2020-2030
    • 21.8.5. Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2020-2030

22. SWOT ANALYSIS

  • 22.1 Chapter Overview
  • 22.2. Strengths
  • 22.3. Weaknesses
  • 22.4. Opportunities
  • 22.5. Threats
  • 22.6. Comparison of SWOT Factors
  • 22.7. Conclusion

23. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

  • 23.1. Chapter Overview
  • 23.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
  • 23.3. Shift from One-time Contracts to Strategic Partnerships
  • 23.4. Integration / Adoption of New and Innovative Technologies
    • 23.4.1. Single use Bioreactors
    • 23.4.2. Novel Bioprocess Techniques
    • 23.4.3. Bioprocess Automation
  • 23.5. Focus on Niche Therapeutic Areas
  • 23.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
  • 23.7. Capability and Expertise Expansions by CMOs to become One-Stop-Shops
  • 23.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
  • 23.9. Increase in Financial Inflow and Outsourcing Budgets
  • 23.10. Challenges Faced by both Sponsors and Service Providers
    • 23.10.1. Concerns Related to Single Use Systems
    • 23.10.2. Issues Related to Capacity Fluctuations
  • 23.11. Concluding Remarks

24. SURVEY ANALYSIS

  • 24.1. Chapter Overview
    • 24.1.1. Overview of Respondents
    • 24.1.2. Analysis by Designation of Respondents
  • 24.2. Analysis by Biologics Manufacturing Expertise
  • 24.3. Analysis by Scale of Manufacturing
  • 24.4. Analysis by Location of Production Facilities
  • 24.5. Analysis by Type of Expression Systems Used
  • 24.6. Analysis by Type of Bioreactors
  • 24.7. Analysis by Mode of Operation of Bioreactors

25. INTERVIEW TRANSCRIPTS

  • 25.1. Chapter Overview
  • 25.2. Andrea Conforto, Sales & Marketing - Bioservices Director, Olon
  • 25.3. Astrid Brammer, Senior Manager Business Development, Richter-Helm
  • 25.4. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie (Q2 2015)
  • 25.5. Christian Bailly, Director of CDMO, Pierre Fabre
  • 25.6. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
  • 25.7. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • 25.8. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • 25.9. Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
  • 25.10. Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
  • 25.11. Kevin Daley, Director Pharmaceuticals, Novasep
  • 25.12. Mark Wright, ex-Site Head, Grangemouth, Piramal Healthcare
  • 25.13. Max Rossetto, General Manager - Business Development, Luina Bio
  • 25.14. Nicolas Grandchamp, R&D Leader, GEG Tech
  • 25.15. Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
  • 25.16. Sebastian Schuck, Head of Business Development, Wacker Biotech
  • 25.17. Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
  • 25.18. Marco Schmeer, Ex-Project Manager And Tatjana Buchholz, Marketing Manager, Plasmid Factory
  • 25.19. Tim Oldham (ex-Chief Executive Officer, Cell Therapies

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Types of Biopharmaceuticals
  • Figure 3.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
  • Figure 3.3 Stages of the Biomanufacturing Process
  • Figure 3.4 Types of Third-Party Service Providers
  • Figure 3.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
  • Figure 4.1 Biopharmaceutical CMOs: Distribution by Year of Establishment
  • Figure 4.2 Biopharmaceutical CMOs: Distribution by Company Size
  • Figure 4.3 Biopharmaceutical CMO: Distribution by Location of Headquarters (Region-
  • Figure 4.4 Biopharmaceutical CMO: Distribution by Location of Headquarters (Country-wise)
  • Figure 4.5 Biopharmaceutical CMOs: Distribution by Company Size, Year of Establishment and Location of Headquarters
  • Figure 4.6 Biopharmaceutical CMOs: Distribution by Type of Product
  • Figure 4.7 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured
  • Figure 4.8 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and
  • Figure 4.9 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Company Size
  • Figure 4.10 Biopharmaceutical CMOs: Distribution by Scale of Operation
  • Figure 4.11 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Scale of Operation
  • Figure 4.12 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used
  • Figure 4.13 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used and Location of Headquarters
  • Figure 4.14 Biopharmaceutical CMOs: Distribution by Types of Bioreactors
  • Figure 4.15 Biopharmaceutical CMOs: Distribution by Mode of Operation of Bioreactors
  • Figure 5.1 Distribution of Biopharmaceutical Contract Manufacturers by Location of Manufacturing Facilities
  • Figure 5.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Product
  • Figure 5.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
  • Figure 5.4 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Types of Expression Systems Used
  • Figure 5.5 Biopharmaceutical Contract Manufacturing Facilities: North America
  • Figure 5.6 Biopharmaceutical Contract Manufacturing Facilities: Europe
  • Figure 5.7 Biopharmaceutical Contract Manufacturing Facilities: Asia-Pacific
  • Figure 6.1 Biopharmaceutical Industry: The US Market Scenario
  • Figure 6.2 Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
  • Figure 6.3 US FDA Guidelines: Elements of a Quality Agreement
  • Figure 6.4 US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations
  • Figure 6.5 AGC: Annual Revenues (JPY Billion)
  • Figure 6.6 Catalent: Service Portfolio
  • Figure 6.7 Catalent: Biosimilars Service Portfolio
  • Figure 6.8 Catalent: Annual Revenues (USD Million)
  • Figure 6.9 Cytiva: Service Portfolio
  • Figure 6.10 Cytiva: Annual Revenues (USD Million)
  • Figure 6.11 FUJIFILM Diosynth Biotechnologies: Service Portfolio
  • Figure 6.12 FUJIFILM Diosynth Biotechnologies: Annual Revenues (JPY Billion)
  • Figure 6.13 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
  • Figure 6.14 KBI Biopharma: Service Portfolio
  • Figure 6.15 Patheon: Service Portfolio
  • Figure 6.16 Patheon: Services and Solutions for Biologics
  • Figure 6.17 Patheon: Annual Revenues (USD Million)
  • Figure 6.18 Piramal Enterprises: Annual Revenues (INR Billion)
  • Figure 7.1 Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
  • Figure 7.2 EMA GMP Guidelines: Key Considerations of the Contract Giver, Contract Acceptor and the Contract
  • Figure 7.3 Boehringer Ingelheim BioXcellence: Service Portfolio
  • Figure 7.4 Boehringer Ingelheim: Annual Revenues (EUR Billion)
  • Figure 7.5 Lonza: Service Portfolio
  • Figure 7.6 Lonza: Annual Revenues (CHF Billion)
  • Figure 7.7 Lonza: Revenues by Business Divisions (CHF Billion)
  • Figure 7.8 Novasep: Products Portfolio
  • Figure 7.9 Novasep: Annual Revenues (EUR Million)
  • Figure 7.10 Rentschler Biopharma: Service Portfolio
  • Figure 7.11 Sandoz: Annual Revenues (USD Billion)
  • Figure 8.1 Chinese Regulatory Guidelines: Key Considerations of the Contract Giver
  • Figure 8.2 Chinese Regulatory Guidelines: Key Considerations of the Contract Acceptor
  • Figure 8.3 Chinese Regulatory Guidelines: Key Aspects of the Contract
  • Figure 8.4 Biopharmaceutical Contract Manufacturing in China: Challenges
  • Figure 8.5 WuXi Biologics: Service Portfolio
  • Figure 8.6 Wuxi Biologics: Annual Revenues (RMB Million)
  • Figure 8.7 Biopharmaceutical Contract Manufacturing in India: Growth Drivers
  • Figure 8.8 Biopharmaceutical Contract Manufacturing in India: Challenges
  • Figure 8.8 Minaris Regenerative Medicine: Service Portfolio
  • Figure 8.9 Takara Bio: Service Portfolio
  • Figure 8.10 Takara Bio: Annual Revenues (CNY Billion)
  • Figure 8.11 Celltrion: Service Portfolio
  • Figure 8.12 Celltrion: Annual Revenues (KRW Billion)
  • Figure 8.13 Samsung BioLogics: Service Portfolio
  • Figure 8.14 Samsung BioLogics: Annual Revenues from CMO Operations (KRW Billion)
  • Figure 8.15 Cell Therapies: Service Portfolio
  • Figure 8.16 Luina Bio: Service Portfolio
  • Figure 9.1 Structure of a Bispecific Antibody
  • Figure 9.2 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
  • Figure 9.3 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
  • Figure 9.4 Structure of an Antibody Drug Conjugate (ADC)
  • Figure 9.5 ADCs Clinical Pipeline: Distribution by Phase of Development
  • Figure 9.6 ADCs Clinical and Commercial Pipeline: Distribution by Target Indication
  • Figure 9.7 ADCs Clinical and Commercial Pipeline: Distribution by Key Technology Providers
  • Figure 9.8 Decentralized Manufacturing: Process Model
  • Figure 9.9 Cell Therapy Manufacturing: Challenges and Growth Drivers
  • Figure 9.10 Cell Therapy: Potency as Critical Quality Attribute
  • Figure 9.11 Stem Cell Therapies: Distribution by Phase of Development
  • Figure 9.12 T-Cell Therapies: Distribution by Phase of Development
  • Figure 9.13 Gene Therapies: Distribution by Stage of Development
  • Figure 9.14 Gene Therapies: Distribution by Phase of Development
  • Figure 9.15 Gene Therapies Clinical and Commercial Pipeline: Distribution by Type of Vector Used
  • Figure 9.16 Gene Therapies Preclinical Pipeline: Distribution by Type of Vector Used
  • Figure 9.17 Gene Therapies Clinical and Commercial Pipeline: Distribution by Target Indication
  • Figure 9.18 Gene Therapies Preclinical Pipeline: Distribution by Target Indication
  • Figure 9.19 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
  • Figure 9.20 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
  • Figure 10.1 Manufacturing Stages of a Biosimilar Product
  • Figure 10.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
  • Figure 10.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
  • Figure 10.4 Need for Outsourcing Biosimilar Manufacturing Operations
  • Figure 10.5 Pipeline Analysis of Biosimilars, 2013 versus 2020
  • Figure 10.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
  • Figure 11.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2020
  • Figure 11.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
  • Figure 12.1 Benefits Associated with In-House Manufacturing
  • Figure 12.2 Risks Associated with In-House Manufacturing
  • Figure 12.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
  • Figure 12.4 Approved Biologics: Distribution by Company Size and Type of Manufacturing Model Adopted
  • Figure 12.5 Approved Biologics: Distribution by Company Size and Types of Biologics Manufactured
  • Figure 13.1 Make versus Buy Decision Making Framework
  • Figure 13.2 Make versus Buy Decision Making: Possible Scenario Descriptions
  • Figure 14.1 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2020
  • Figure 14.2 Big Pharma Players: Cumulative Distribution by Year of Initiative
  • Figure 14.3 Big Pharma Players: Distribution by Purpose of Initiative
  • Figure 14.4 Big Pharma Players: Distribution by Type of Initiative
  • Figure 14.5 Big Pharma Players: Distribution by Type of Partnership
  • Figure 14.6 Big Pharma Players: Distribution by Type of Expansion
  • Figure 14.7 Big Pharma Players: Distribution by Scale of Operation
  • Figure 14.8 Big Pharma Players: Distribution by Types of Biologics Manufactured
  • Figure 14.9 Big Pharma Players: Distribution by Year of Initiative and Company
  • Figure 14.10 Big Pharma Players: Distribution by Purpose of Initiative and Company
  • Figure 14.11 Big Pharma Players: Distribution by Year and Type of Initiative
  • Figure 14.12 Big Pharma Players: Distribution by Region of Expansion and Company
  • Figure 14.13 Big Pharma Players: Distribution by Types of Biologics Manufactured and Company
  • Figure 14.14 Harvey Ball Analysis: Big Pharma Investment Summary
  • Figure 15.1 Partnerships and Collaborations: Cumulative Trend by Year, 2015-2020
  • Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership Model Adopted
  • Figure 15.3 Partnerships and Collaborations: Distribution by Focus Area
  • Figure 15.4 Partnerships and Collaborations: Distribution by Focus Area and Type of Partnership Model Adopted
  • Figure 15.5 Partnerships and Collaborations: Distribution by Year and Type of Partnership Model Adopted
  • Figure 15.6 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured
  • Figure 15.7 Partnerships and Collaborations: Distribution by Year and Types of Biologics Manufactured
  • Figure 15.8 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured and Type of Partnership Model
  • Figure 15.9 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured and Geography
  • Figure 15.10 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 15.11 Most Active Players: Distribution by Number of Partnerships
  • Figure 15.12 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 15.13 Partnerships and Collaborations: Distribution by Geographical Location (Local and International)
  • Figure 16.1 Mergers and Acquisitions: Year-Wise Cumulative Trend (2015- 2020)
  • Figure 16.2 Mergers and Acquisitions: Distribution by Type of Acquisition
  • Figure 16.3 Mergers and Acquisitions: Distribution by Region (Continent-wise)
  • Figure 16.4 Mergers and Acquisitions: Distribution by Region (Country-wise)
  • Figure 16.5 Mergers and Acquisitions: Distribution by Intercontinental and Intracontinental Deals
  • Figure 16.6 Most Active Acquirers: Distribution by Number of Acquisitions
  • Figure 16.7 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Figure 16.8 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
  • Figure 16.9 Mergers and Acquisitions: Distribution by Types of Biologics Manufactured
  • Figure 16.10 Heat Map Analysis: Distribution by Types of Biologics Manufactured and Key Value Drivers
  • Figure 16.11 Mergers and Acquisitions: Deal Multiples Based on Revenue
  • Figure 17.1 Facility Expansions: Cumulative Year-wise Trend, 2016-2020
  • Figure 17.2 Facility Expansions: Distribution by Purpose of Expansion
  • Figure 17.3 Facility Expansions: Distribution by Year and Purpose of Expansion
  • Figure 17.4 Facility Expansions: Distribution by Types of Biologics Manufactured
  • Figure 17.5 Facility Expansions: Distribution by Types of Biologics Manufactured and Purpose of Expansion
  • Figure 17.6 Facility Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
  • Figure 17.7 Facility Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
  • Figure 17.8 Facility Expansions: Most Active Players
  • Figure 17.9 Facility Expansions: Distribution by Location of Headquarters and Purpose of Expansion
  • Figure 17.10 Facility Expansions: Regional Comparison 2016-2018 and 2016-2020 Scenario
  • Figure 19.1 Biopharma CMOs Global Capacity: Distribution by Range of Installed Capacity
  • Figure 19.2 Capacity Analysis: Distribution by Company Size
  • Figure 19.3 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Types of Expression Systems Used
  • Figure 19.4 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Scale of Operation
  • Figure 19.5 Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
  • Figure 19.6 Capacity Analysis: Contract Biomanufacturing Capacity in the US
  • Figure 19.7 Capacity Analysis: Contract Biomanufacturing Capacity in Canada
  • Figure 19.8 Capacity Analysis: Contract Biomanufacturing Capacity in the UK
  • Figure 19.9 Capacity Analysis: Contract Biomanufacturing Capacity in Germany
  • Figure 19.10 Capacity Analysis: Contract Biomanufacturing Capacity in France
  • Figure 19.11 Capacity Analysis: Contract Biomanufacturing Capacity in Italy
  • Figure 19.12 Capacity Analysis: Contract Biomanufacturing Capacity in Spain
  • Figure 19.13 Capacity Analysis: Contract Biomanufacturing Capacity in Rest of Europe
  • Figure 19.14 Capacity Analysis: Contract Biomanufacturing Capacity in China
  • Figure 19.15 Capacity Analysis: Regional Contract Biomanufacturing Capacity in South Korea
  • Figure 19.16 Capacity Analysis: Regional Contract Biomanufacturing Capacity in Taiwan
  • Figure 19.17 Capacity Analysis: Regional Contract Biomanufacturing Capacity in India
  • Figure 19.18 Capacity Analysis: Regional Contract Biomanufacturing Capacity in Japan
  • Figure 19.19 Capacity Analysis: Regional Contract Biomanufacturing Capacity in Rest of Asia-Pacific
  • Figure 20.1 Demand Analysis: Annual Demand for Biopharmaceutical Manufacturing, 2020-2030 (in kg)
  • Figure 20.2 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
  • Figure 20.3 Biologics: Demand and Supply Scenario, 2020-2030 (Million Liters)
  • Figure 20.4 Demand Analysis: Annual Demand for ADC Therapeutics (in kg), 2020-2030
  • Figure 20.5 ADC Therapeutics: Demand and Supply Scenario, 2020-2030
  • Figure 20.6 Global Demand for Cell Therapies, 2019-2030 (Number of Patients)
  • Figure 20.7 Global Demand for Cell Therapies, 2019-2030 (Billion Cells)
  • Figure 21.1 Biopharmaceutical Contract Manufacturing: Market Forecast Framework
  • Figure 21.2 Global Biopharmaceutical Contract Manufacturing Market, 2020-2030 (USD Billion)
  • Figure 21.3 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2020-2030 (USD Billion)
  • Figure 21.4 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2020-2030 (USD Billion)
  • Figure 21.5 Biopharmaceutical Contract Manufacturing Market for Others, 2020-2030 (USD Billion)
  • Figure 21.6 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Expression Systems Used (USD Billion)
  • Figure 21.7 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
  • Figure 21.8 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
  • Figure 21.9 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Biologics Manufactured (USD Billion)
  • Figure 21.10 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
  • Figure 21.11 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
  • Figure 21.12 Biopharmaceutical Contract Manufacturing Market in the US, 2020-2030 (USD Billion)
  • Figure 21.13 Biopharmaceutical Contract Manufacturing Market in Canada, 2020-2030 (USD Billion)
  • Figure 21.14 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
  • Figure 21.15 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
  • Figure 21.16 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
  • Figure 21.17 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 21.18 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Operations (USD Billion)
  • Figure 21.19 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
  • Figure 21.20 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 21.21 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 21.22 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Antibody Therapeutics (USD Billion)
  • Figure 21.23 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Vaccines (USD Billion)
  • Figure 21.24 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Cell Therapies (USD Billion)
  • Figure 21.25 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
  • Figure 21.26 Biopharmaceutical Contract Manufacturing Market in Italy, 2020-2030 (USD Billion)
  • Figure 21.27 Biopharmaceutical Contract Manufacturing Market in Germany, 2020-2030 (USD Billion)
  • Figure 21.28 Biopharmaceutical Contract Manufacturing Market in France, 2020-2030 (USD Billion)
  • Figure 21.29 Biopharmaceutical Contract Manufacturing Market in Spain, 2020-2030 (USD Billion)
  • Figure 21.30 Biopharmaceutical Contract Manufacturing Market in the UK, 2020-2030 (USD Billion)
  • Figure 21.31 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2020-2030 (USD Billion)
  • Figure 21.32 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
  • Figure 21.33 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
  • Figure 21.34 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
  • Figure 21.35 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 21.36 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations (USD Billion)
  • Figure 21.37 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
  • Figure 21.38 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 21.39 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 21.40 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Antibody Therapeutics (USD Billion)
  • Figure 21.41 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Vaccines (USD Billion)
  • Figure 21.42 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Cell Therapies (USD Billion)
  • Figure 21.43 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 21.44 Biopharmaceutical Contract Manufacturing Market in China, 2020-2030 (USD Billion)
  • Figure 21.45 Biopharmaceutical Contract Manufacturing Market in India, 2020-2030 (USD Billion)
  • Figure 21.46 Biopharmaceutical Contract Manufacturing Market in South Korea, 2020-2030 (USD Billion)
  • Figure 21.47 Biopharmaceutical Contract Manufacturing Market in Japan, 2020-2030 (USD Billion)
  • Figure 21.48 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 21.49 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
  • Figure 21.50 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
  • Figure 21.51 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
  • Figure 21.52 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Preclinical / Clinical Operations (USD Billion)
  • Figure 21.53 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Commercial Operations (USD Billion)
  • Figure 21.54 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Small Companies (USD Billion)
  • Figure 21.55 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mid-sized Companies (USD Billion)
  • Figure 21.56 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Large / Very Large Companies (USD Billion)
  • Figure 21.57 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Antibody Therapeutics (USD Billion)
  • Figure 21.58 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Vaccines (USD Billion)
  • Figure 21.59 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Cell Therapies (USD Billion)
  • Figure 21.60 Biopharmaceutical Contract Manufacturing Market in Latin America, 2020-2030 (USD Billion)
  • Figure 21.61 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2020-2030 (USD Billion)
  • Figure 22.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
  • Figure 22.2 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2002-2020
  • Figure 22.3 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 24.1 Survey Analysis: Distribution of Respondents by Company Type
  • Figure 24.2 Survey Analysis: Distribution of Respondents by Location of Headquarters
  • Figure 24.3 Survey Analysis: Distribution of Respondents by Designation
  • Figure 24.4 Survey Analysis: Distribution by Biologics Manufacturing Expertise
  • Figure 24.5 Survey Analysis: Distribution by Scale of Manufacturing
  • Figure 24.6 Survey Analysis: Distribution by Location of Production Facilities
  • Figure 24.7 Survey Analysis: Distribution by Types of Expression Systems Used
  • Figure 24.8 Survey Analysis: Distribution by Types of Bioreactors
  • Figure 24.9 Survey Analysis: Distribution by Mode of Operation of Bioreactors

List Of Tables

  • Table 3.1 Mammalian versus Microbial Expression Systems
  • Table 4.1 List of Biopharmaceutical CMOs
  • Table 4.2 Biopharmaceutical CMOs: Information on Type of Product
  • Table 4.3 Biopharmaceutical CMOs: Information on Types of Biologics Manufactured
  • Table 4.4 Biopharmaceutical CMOs: Information on Scale of Operation,
  • Table 4.5 Biopharmaceutical CMOs: Information on Types of Expression Systems Used,
  • Table 4.6 Biopharmaceutical CMOs: Information on Types of Bioreactors,
  • Table 4.7 Biopharmaceutical CMOs: Information on Mode of Operation of Bioreactors,
  • Table 5.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
  • Table 5.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
  • Table 5.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
  • Table 6.1 AGC Biologics: Company Overview
  • Table 6.2 AGC Biologics: Biologics Manufacturing Facilities
  • Table 6.3 AGC Biologics: Partnerships
  • Table 6.4 AGC Biologics: Recent Expansions
  • Table 6.6 Catalent: Company Overview
  • Table 6.7 Catalent: Biologics Manufacturing Facilities
  • Table 6.8 Catalent: Partnerships
  • Table 6.9 Catalent: Recent Expansions
  • Table 6.11 Cytiva: Company Overview
  • Table 6.12 Cytiva: Manufacturing Facilities
  • Table 6.13 Cytiva: Partnerships
  • Table 6.14 Cytiva: Recent Expansions
  • Table 6.16 FUJIFILM Diosynth Biotechnologies: Company Overview
  • Table 6.17 FUJIFILM Diosynth Biotechnologies: Biopharmaceutical Facilities
  • Table 6.18 FUJIFILM Diosynth Biotechnologies: Partnerships
  • Table 6.19 FUJIFILM Diosynth Biotechnologies: Recent Expansions
  • Table 6.21 KBI Biopharma: Company Overview
  • Table 6.22 KBI Biopharma: Overview of Manufacturing Capabilities
  • Table 6.23 KBI Biopharma: List of Partnerships
  • Table 6.25 Patheon: Company Overview
  • Table 6.26 Patheon: Biopharmaceutical Manufacturing and Development Facilities
  • Table 6.27 Patheon: Partnerships
  • Table 6.28 Patheon: Recent Expansions
  • Table 6.30 Piramal Pharma Solutions: Company Overview
  • Table 6.31 Piramal Pharma Solutions: Facilities
  • Table 7.1 FDA Quality Agreement and EMA cGMP Regulations: A Comparative Analysis
  • Table 7.2 Boehringer Ingelheim: Company Overview
  • Table 7.3 Boehringer Ingelheim: Biopharmaceutical Facilities
  • Table 7.4 Boehringer Ingelheim: Partnerships
  • Table 7.5 Boehringer Ingelheim: Recent Expansions
  • Table 7.7 Lonza: Company Overview
  • Table 7.8 Lonza: Biopharmaceutical Facilities
  • Table 7.9 Lonza: Partnerships
  • Table 7.10 Lonza: Recent Expansions
  • Table 7.12 Novasep: Company Overview
  • Table 7.13 Novasep: Biologics Manufacturing Facilities
  • Table 7.14 Novasep: Partnerships
  • Table 7.15 Novasep: Recent Expansions
  • Table 7.17 Olon: Company Overview
  • Table 7.18 Olon: Biopharmaceutical Facilities
  • Table 7.20 Rentschler Biopharma: Company Overview
  • Table 7.21 Rentschler Biopharma: Partnerships
  • Table 7.22 Rentschler Biopharma: Recent Expansions
  • Table 7.24 Sandoz: Company Overview
  • Table 8.1 WuXi AppTec (WuXi Biologics): Company Overview
  • Table 8.2 WuXi Biologics: Partnerships
  • Table 8.3 WuXi Biologics: Recent Expansions
  • Table 8.4 WuXi Biologics: Future Outlook
  • Table 8.5 Kemwell Biopharma: Company Overview
  • Table 8.6 Kemwell Biopharma: Partnerships
  • Table 8.7 Kemwell Biopharma: Recent Expansions
  • Table 8.8 Minaris Regenerative Medicine: Company Overview
  • Table 8.9 Minaris Regenerative Medicine: Manufacturing Facilities
  • Table 8.10 Minaris Regenerative Medicine: Partnerships
  • Table 8.11 Minaris Regenerative Medicine: Future Outlook
  • Table 8.12 Takara Bio: Company Overview
  • Table 8.13 Takara Bio: Biologics Manufacturing Facilities
  • Table 8.14 Takara Bio: Future Outlook
  • Table 8.15 Celltrion: Company Overview
  • Table 8.16 Celltrion: Biologics Manufacturing Facilities
  • Table 8.17 Celltrion: Future Outlook
  • Table 8.18 Samsung BioLogics: Company Overview
  • Table 8.19 Samsung BioLogics: Biopharmaceutical Facilities
  • Table 8.20 Samsung BioLogics: Partnerships
  • Table 8.21 Samsung BioLogics: Recent Expansions
  • Table 8.22 Samsung BioLogics: Future Outlook
  • Table 8.23 Cell Therapies: Company Overview
  • Table 8.24 Cell Therapies: Partnerships
  • Table 8.25 Cell Therapies: Future Outlook
  • Table 8.26 Luina Bio: Company Overview
  • Table 8.27 Luina Bio: Partnerships
  • Table 8.28 LuinaBio: Recent Expansions
  • Table 8.29 Luina Bio: Future Outlook
  • Table 9.1 Bispecific Antibody Therapeutics: Information on Developer(s), Platform / Technology Used, Phase of Development, Target Antigen and Antibody Format,
  • Table 9.2 Bispecific Antibody Therapeutics: Information on Developer(s), Technology used, Phase of Development, Target Antigens, Mechanism of Action, Disease Indication, Therapeutic Area and Broader Disease Segment
  • Table 9.3 List of Other Emerging Multivalent Drug Candidates
  • Table 9.4 Bispecific Antibody Therapeutics: List of Technology Platforms,
  • Table 9.5 List of Bispecific Antibody CMOs: Information on Company Specifications
  • Table 9.6 Commonly Used Cytotoxins for ADC Therapeutics
  • Table 9.7 Occupational Exposure Limit Bands, Safebridge Consultants
  • Table 9.8 ADC Therapeutics: Approved / Clinical Pipeline
  • Table 9.8 Novel Drug Conjugates
  • Table 9.10 ADC Contract Manufacturing Service Providers: List of Companies
  • Table 9.11 Application of Cell-based Therapies
  • Table 9.12 Cell-based Therapies: Commercialized Products,
  • Table 9.13 Assessments for Key Cell Therapy Manufacturing Steps
  • Table 9.14 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 9.15 Cell Therapy Contract Manufacturers: Type of Cell Therapy
  • Table 9.16 List of Cell Therapy Contract Manufacturers
  • Table 9.17 Viral Vectors Manufacturers: Information on Type of Viral Vector Used
  • Table 9.18 Viral Vectors: List of Manufacturers
  • Table 9.19 Plasmid DNA: List of Manufacturers
  • Table 10.1 Biosimilars Pipeline Analysis: Distribution by Drug Class, 2013 and 2020
  • Table 10.2 Biosimilar Pipeline Analysis: Distribution by Reference Products, 2013 and 2020
  • Table 10.3 List of Biosimilars Contract Manufacturing Service Providers
  • Table 11.1 Small Molecules and Large Molecules: Strengths and Weaknesses
  • Table 11.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
  • Table 11.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
  • Table 12.1 List of FDA Approved Biologics (2016-2020)
  • Table 14.1 Big Pharma Players: List of Biopharmaceutical Manufacturing Initiatives
  • Table 15.1 Biopharmaceutical Contract Manufacturing: List of Collaborations, 2015 - 2020
  • Table 15.2 Biopharmaceutical Contract Manufacturing Partnerships and Collaborations: Information on Types of Biologics Manufactured,
  • Table 16.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, 2015 - 2020
  • Table 16.2 Biopharmaceutical Contract Manufacturing Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologics, 2015- 2020
  • Table 16.3 Mergers and Acquisitions: Deal Multiples, 2015- 2020
  • Table 17.1 Biopharmaceutical Contract Manufacturing: List of Expansions
  • Table 18.1 Biopharmaceutical CMOs: Funding Instances
  • Table 19.1 Capacity Analysis: Information on Contract Biomanufacturing Capacity
  • Table 19.2 Capacity Analysis: Average Capacity per Category
  • Table 19.3 Capacity Analysis: Average Capacity for Mammalian Expression Systems
  • Table 19.4 Capacity Analysis: Average Capacity for Microbial Expression Systems
  • Table 19.5 Capacity Analysis: Global Contract Biomanufacturing Capacity
  • Table 20.1 Annual Biomanufacturing Capacity, 2019-2024 (Million Liters)
  • Table 20.2 ADC Therapeutics: Annual Demand for Outsourcing, 2020-2030 (in kg)
  • Table 20.3 ADC Therapeutics: Annual Supply for Outsourcing, 2018-2030 (in Kilograms)
  • Table 22.1 Global Biopharmaceuticals Market: Patent Approval and Expiry Details of Best-selling Biologics
  • Table 24.1 Survey Analysis: Overview of Respondents
  • Table 24.2 Survey Analysis: Distribution of Respondents by Designation
  • Table 24.3 Survey Analysis: Biologics Manufacturing Expertise
  • Table 24.4 Survey Analysis: Scale of Manufacturing
  • Table 24.5 Survey Analysis: Location of Production Facilities
  • Table 24.6 Survey Analysis: Types of Expression Systems Used
  • Table 24.7 Survey Analysis: Types of Bioreactors
  • Table 24.8 Survey Analysis: Mode of Operation of Bioreactors
  • Table 26.1 Biopharmaceutical CMOs: Distribution by Year of Establishment
  • Table 26.2 Biopharmaceutical CMOs: Distribution by Company Size
  • Table 26.3 Biopharmaceutical CMO: Distribution by Location of Headquarters (Region-wise)
  • Table 26.4 Biopharmaceutical CMO: Distribution by Location of Headquarters (Country-wise)
  • Table 26.5 Biopharmaceutical CMOs: Distribution by Type of Product
  • Table 26.6 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured
  • Table 26.7 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Location of Headquarters
  • Table 26.8 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Company Size
  • Table 26.9 Biopharmaceutical CMOs: Distribution by Scale of Operation
  • Table 26.10 Biopharmaceutical CMOs: Distribution by Types of Biologics Manufactured and Scale of Operation
  • Table 26.11 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used
  • Table 26.12 Biopharmaceutical CMOs: Distribution by Types of Expression Systems Used and Location of Headquarters
  • Table 26.13 Biopharmaceutical CMOs: Distribution by Types of Bioreactors
  • Table 26.14 Biopharmaceutical CMOs: Distribution by Mode of Operation of Bioreactor
  • Table 26.15 Distribution of Biopharmaceutical Contract Manufacturers by Location of Manufacturing Facilities
  • Table 26.16 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Product
  • Table 26.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
  • Table 26.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Types of Expression Systems Used
  • Table 26.19 AGC Biologics: Annual Revenues (JPY Billion)
  • Table 26.20 Catalent: Annual Revenues (USD Million)
  • Table 26.21 Cytiva: Annual Revenues (USD Million)
  • Table 26.22 FUJIFILM Diosynth Biotechnologies: Annual Revenues (JPY Billion)
  • Table 26.23 FUJIFILM Holdings: Annual Revenues by Business Divisions (JPY Billion)
  • Table 26.24 Patheon: Annual Revenues (USD Million)
  • Table 26.25 Piramal Enterprises: Annual Revenues (INR Billion)
  • Table 26.26 Boehringer Ingelheim: Annual Revenues (EUR Billion)
  • Table 26.27 Lonza: Annual Revenues (CHF Billion)
  • Table 26.28 Lonza: Annual Revenues by Business Divisions (CHF Billion)
  • Table 26.29 Novasep: Annual Revenues (EUR Million)
  • Table 26.30 Sandoz: Annual Revenues (USD Million)
  • Table 26.31 Wuxi Biologics: Annual Revenues (RMB Million)
  • Table 26.32 Celltrion: Annual Revenues (KRW Billion)
  • Table 26.33 Samsung Biologics: Annual Revenues from CMO Operations (KRW Billion)
  • Table 26.34 Bispecific Antibody Therapeutics Pipeline: Distribution by Phase of Development
  • Table 26.35 Bispecific Antibody Therapeutics Pipeline: Distribution by Target Indication
  • Table 26.36 ADCs Clinical Pipeline: Distribution by Phase of Development
  • Table 26.37 ADCs Clinical and Commercial Pipeline: Distribution by Target Indication
  • Table 26.38 ADCs Clinical and Commercial Pipeline: Distribution by Key Technology Providers
  • Table 26.39 Stem Cell Therapies: Distribution by Phase of Development
  • Table 26.40 T-Cell Therapies: Distribution by Phase of Development
  • Table 26.41 Gene Therapies Pipeline: Distribution by Stage of Development
  • Table 26.42 Gene Therapies Pipeline: Distribution by Phase of Development
  • Table 26.43 Gene Therapies Clinical and Commercial Pipeline: Distribution by Type of Vector Used
  • Table 26.44 Gene Therapies Preclinical Pipeline: Distribution by Type of Vector Used
  • Table 26.45 Gene Therapies Clinical and Commercial Pipeline: Distribution by Target Indication
  • Table 26.46 Gene Therapies Preclinical Pipeline: Distribution by Target Indication
  • Table 26.47 Viral Vector Manufacturers: Distribution by Location of Manufacturing Facility
  • Table 26.48 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
  • Table 26.49 Pipeline Analysis of Biosimilars, 2013 versus 2020
  • Table 26.50 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2020
  • Table 26.51 Approved Biologics: Distribution by Company Size and Type of Manufacturing Model Adopted
  • Table 26.52 Approved Biologics: Distribution by Company Size and Types of Biologics Manufactured
  • Table 26.53 Big Pharma Players: Distribution by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives, 1980-2020
  • Table 26.54 Big Pharma Players: Cumulative Distribution by Year of Initiative
  • Table 26.55 Big Pharma Players: Distribution by Purpose of Initiative
  • Table 26.56 Big Pharma Players: Distribution by Type of Initiative
  • Table 26.57 Big Pharma Players: Distribution by Type of Partnership
  • Table 26.58 Big Pharma Players: Distribution by Type of Expansion
  • Table 26.59 Big Pharma Players: Distribution by Scale of Operation
  • Table 26.60 Big Pharma Players: Distribution by Types of Biologics Manufactured
  • Table 26.61 Big Pharma Players: Distribution by Purpose of Initiative and Company
  • Table 26.62 Big Pharma Players: Distribution by Year and Type of Initiative
  • Table 26.63 Big Pharma Players: Distribution by Region of Expansion and Company
  • Table 26.64 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 26.65 Partnerships and Collaborations: Distribution by Type of Partnership Model Adopted
  • Table 26.66 Partnerships and Collaborations: Distribution by Focus Area
  • Table 26.67 Partnerships and Collaborations: Distribution by Focus Area and Type of Partnership Model
  • Table 26.68 Partnerships and Collaborations: Distribution by Year and Type of Partnership Model Adopted
  • Table 26.69 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured
  • Table 26.70 Partnerships and Collaborations: Distribution by Year of Partnership and Types of Biologics Manufactured
  • Table 26.71 Partnerships and Collaborations: Distribution by Types of Biologics Manufactured and Type of Partnership Model Adopted
  • Table 26.72 Partnerships and Collaborations: Distribution of Manufacturing Agreements by Types of Biologics Manufactured and Geography
  • Table 26.73 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 26.74 Partnerships and Collaborations: Most Active Players
  • Table 26.75 Partnerships and Collaborations: Distribution by Most Active Players and Type of Partnership
  • Table 26.76 Partnerships and Collaborations: Distribution by Geographical Location (Local and International Agreements)
  • Table 26.77 Mergers and Acquisitions: Year-Wise Cumulative Trend (2015- 2020)
  • Table 26.78 Mergers and Acquisitions: Distribution by Type of Acquisition
  • Table 26.79 Mergers and Acquisitions: Distribution by Region (Continent-wise)
  • Table 26.80 Mergers and Acquisitions: Distribution by Region (Country-wise)
  • Table 26.81 Most Active Acquirers: Distribution by Number of Acquisitions
  • Table 26.82 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Table 26.83 Mergers and Acquisitions: Distribution by Key Value Drivers and Year of Acquisition
  • Table 26.84 Mergers and Acquisitions: Distribution by Types of Biologics Manufactured
  • Table 26.85 Mergers and Acquisitions: Deal Multiples Based on Revenue
  • Table 26.86 Mergers and Acquisitions: Deal Multiples Based on Revenue
  • Table 26.87 Facility Expansions: Cumulative Year-wise Trend, 2016-2020
  • Table 26.88 Facility Expansions: Distribution by Purpose of Expansion
  • Table 26.89 Facility Expansions: Distribution by Year of Expansion and Purpose of Expansion
  • Table 26.90 Facility Expansions: Distribution by Types of Biologics Manufactured
  • Table 26.91 Facility Expansions: Distribution by Types of Biologics Manufactured and Purpose of Expansion
  • Table 26.92 Facility Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
  • Table 26.93 Facility Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
  • Table 26.94 Facility Expansions: Most Active Players
  • Table 26.95 Facility Expansions: Distribution by Location of Headquarters and Purpose of Expansion
  • Table 26.96 Capacity Analysis: Distribution by Company Size
  • Table 26.97 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Types of Expression Systems Used
  • Table 26.98 Capacity Analysis: Global Contract Biomanufacturing Capacity based on Scale of Operation
  • Table 26.99 Capacity Analysis: Regional Distribution of Biopharmaceutical CMOs
  • Table 26.100 Demand Analysis: Annual Demand for Biopharmaceutical Manufacturing, 2020-2030 (in kg)
  • Table 26.101 Demand Analysis: Distribution of Annual Demand by Therapeutic Area
  • Table 26.102 Demand Analysis: Annual Demand for ADC Therapeutics (in kg), 2020-2030
  • Table 26.103 Global Demand for Cell Therapies, 2019-2030 (Number of Patients)
  • Table 26.104 Global Demand for Cell Therapies, 2019-2030 (Billion Cells)
  • Table 26.105 Global Biopharmaceutical Contract Manufacturing Market, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.106 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.107 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.108 Biopharmaceutical Contract Manufacturing Market for Others, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.109 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Expression Systems Used (USD Billion)
  • Table 26.110 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
  • Table 26.111 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Company Size USD Billion)
  • Table 26.112 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Types of Biologics Manufactured (USD Billion)
  • Table 26.113 Biopharmaceutical Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
  • Table 26.114 Biopharmaceutical Contract Manufacturing Market in North America: 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.115 Biopharmaceutical Contract Manufacturing Market in the US, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.116 Biopharmaceutical Contract Manufacturing Market in Canada, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.117 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.118 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.119 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.120 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.121 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.122 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.123 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.124 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.125 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Antibody Therapeutics, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.126 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Vaccines, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.127 Biopharmaceutical Contract Manufacturing Market in North America, 2020-2030: Share of Cell Therapies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.128 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 26.129 Biopharmaceutical Contract Manufacturing Market in Italy, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.130 Biopharmaceutical Contract Manufacturing Market in Germany, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.131 Biopharmaceutical Contract Manufacturing Market in France, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.132 Biopharmaceutical Contract Manufacturing Market in Spain, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.133 Biopharmaceutical Contract Manufacturing Market in the UK, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.134 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.135 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.136 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.137 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.138 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.139 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.140 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.141 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.142 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.143 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Antibody Therapeutics, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.144 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Vaccines, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.145 Biopharmaceutical Contract Manufacturing Market in Europe, 2020-2030: Share of Cell Therapies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.146 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific: 2020-2030, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.147 Biopharmaceutical Contract Manufacturing Market in China, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.148 Biopharmaceutical Contract Manufacturing Market in India, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.149 Biopharmaceutical Contract Manufacturing Market in South Korea, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.150 Biopharmaceutical Contract Manufacturing Market in Japan, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.151 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.152 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mammalian Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.153 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Microbial Cell-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.154 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Other Expression System-based Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.155 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Preclinical / Clinical Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.156 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Commercial Operations, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.157 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Small Companies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.158 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Mid-sized Companies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.159 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Large / Very Large Companies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.160 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Antibody Therapeutics, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.161 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Vaccines, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.162 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, 2020-2030: Share of Cell Therapies, Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.163 Biopharmaceutical Contract Manufacturing Market in Latin America, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.164 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2020-2030: Conservative, Base and Optimistic Scenario (USD Billion)
  • Table 26.165 Global Biopharmaceuticals Market: Number of FDA Approvals by Year, 2002-2020
  • Table 26.166 Survey Analysis: Distribution of Respondents by Company Type
  • Table 26.167 Survey Analysis: Distribution of Respondents by Location of Headquarters
  • Table 26.168 Survey Analysis: Distribution of Respondents by Designation
  • Table 26.169 Survey Analysis: Distribution by Biologics Manufacturing Expertise
  • Table 26.170 Survey Analysis: Distribution by Scale of Manufacturing
  • Table 26.171 Survey Analysis: Distribution by Location of Production Facilities
  • Table 26.172 Survey Analysis: Distribution by Types of Expression Systems Used
  • Table 26.173 Survey Analysis: Distribution by Types of Bioreactors
  • Table 26.174 Survey Analysis: Distribution by Mode of Operation of Bioreactors

List Of Companies

  • 1. 3P Biopharmaceuticals
  • 2. 3SBio
  • 3. 53 Biologics
  • 4. A.R. BROWN
  • 5. Aalto Scientific
  • 6. Labyrinth BioPharma (Formely known as AB BioTechnologies)
  • 7. AbbVie Contract Manufacturing
  • 8. AbCellera Biologics
  • 9. Abeona Therapeutics
  • 10. ABL
  • 11. ABL Bio
  • 12. Abzena
  • 13. Acasti Pharma
  • 14. Accellta
  • 15. ACES Pharma
  • 16. Achilles Therapeutics
  • 17. Acticor Biotech
  • 18. Adagene
  • 19. Adaptimmune
  • 20. AdaptVac
  • 21. ADC Bio
  • 22. Adimmune
  • 23. Advanced Biotherapeutics Consulting
  • 24. Advanced Cell Technology
  • 25. Advanced Scientifics (Acquired by Thermo Fisher Scientific)
  • 26. Advanced Therapy Treatment Centre (ATTC)
  • 27. Advaxis
  • 28. Advent Bioservices
  • 29. Aeras
  • 30. Affibody
  • 31. Affinita Biotech
  • 32. Affinity Life Sciences
  • 33. Affymetrix
  • 34. Afton Scientific
  • 35. AGC Biologics
  • 36. Agilis Biotherapeutics
  • 37. Agilux Laboratories
  • 38. Airway Therapeutics
  • 39. Ajinomoto Althea
  • 40. Ajinomoto Bio-Pharma Services
  • 41. Ajinomoto OmniChem
  • 42. Akorn
  • 43. Akouos
  • 44. Akron Biotech
  • 45. Akshaya Bio
  • 46. Alcami
  • 47. Aldevron
  • 48. Alexion
  • 49. Allele Biotechnology & Pharmaceuticals
  • 50. Allevi
  • 51. Alliance Protein Laboratories APL (Acquired by KBI Biopharma)
  • 52. Alligator Bioscience
  • 53. Almac Group
  • 54. Altor BioScience
  • 55. Amaran Biotechnology
  • 56. Amatsigroup (Acquired by Eurofins)
  • 57. AmbioPharm
  • 58. American Peptide Company (Acquired by Bachem)
  • 59. Amgen
  • 60. Andes Biotechnologies
  • 61. Antabio
  • 62. Anthos Therapeutics
  • 63. apceth Biopharma
  • 64. Aptevo Therapeutics
  • 65. Aravive
  • 66. Arch Biopartners
  • 67. Arcturus Therapeutics
  • 68. Arcus Biosciences
  • 69. Arecor
  • 70. argenx
  • 71. Ash Stevens
  • 72. ASLAN Pharmaceuticals
  • 73. Asterias Biotherapeutics
  • 74. AstraZeneca
  • 75. Asymchem
  • 76. Asymptote (Acquired by GE Healthcare)
  • 77. Athersys
  • 78. Austrianova
  • 79. AutekBio
  • 80. Autolus
  • 81. Avecia (acquired by Nitto Denko)
  • 82. Avid Bioservices
  • 83. Avrio Biopharmaceuticals
  • 84. Axcellerate Pharma
  • 85. Axovant Sciences
  • 86. Babraham Bioscience Technologies
  • 87. Baccinex
  • 88. Bachem
  • 89. Batavia Biosciences
  • 90. Battelle
  • 91. Baxter BioPharma Solutions
  • 92. Baylor College of Medicine
  • 93. Baylor Institute for Immunology Research
  • 94. Baylor Scott & White Research Institute (BSWRI)
  • 95. BCN Peptides
  • 96. BDI biotech
  • 97. Beam Therapeutics
  • 98. BeiGene
  • 99. Beijing Kawin Bio-Tech
  • 100. Berkeley Lights
  • 101. Bexion Pharmaceuticals
  • 102. Bioindustry Association (BIA) BIA Separations
  • 103. BIBITEC
  • 104. Bill & Melinda Gates Foundation
  • 105. BINEX
  • 106. Bio Elpida
  • 107. Bioasis
  • 108. BioCell
  • 109. BioConnection
  • 110. Bio-Ess Laboratories
  • 111. Biofabri
  • 112. Bio Farma
  • 113. Bioinova
  • 114. BioInvent
  • 115. Biological E.
  • 116. BioMARC
  • 117. Biomay
  • 118. BioMeca
  • 119. Biomedical Advanced Research and Development Authority (BARDA)
  • 120. Biomeva (Acquired by AGC Biologics)
  • 121. BiondVax Pharmaceuticals
  • 122. Bionova Scientific
  • 123. BioNTech
  • 124. Biopolis Lifesciences
  • 125. BiosanaPharma
  • 126. BioSig Technologies
  • 127. Biospring Partners
  • 128. Bio-Synergy
  • 129. Bio-Synthesis
  • 130. BioTechnique
  • 131. Biotechpharma
  • 132. BioVectra
  • 133. Bioverativ
  • 134. Biovian
  • 135. Bioworkshops
  • 136. BioXcellence
  • 137. Bliss Biopharmaceutical
  • 138. Blue Stream Laboratories
  • 139. bluebird bio
  • 140. Boehringer Ingelheim
  • 141. Boston Children's Hospital
  • 142. BPL Biologics
  • 143. Brammer Bio
  • 144. Bristol Myers Squibb
  • 145. Bryllan
  • 146. BSP Pharmaceuticals
  • 147. Burrard Pharmaceuticals
  • 148. C3i Solutions
  • 149. Plasma Industries Belgium (Formely known as CAF-DCF)
  • 150. Caisson Biotech
  • 151. Calviri
  • 152. Calypso Biotech
  • 153. Cambridge Pharmaceuticals
  • 154. CANbridge
  • 155. Cancer Research Technology
  • 156. Canton Biologics
  • 157. Capsugel
  • 158. Capua BioServices
  • 159. CARBOGEN AMCIS
  • 160. Catalent Biologics
  • 161. Catalyst Biosciences
  • 162. CDR-Life
  • 163. Cell and Gene Therapy Catapult
  • 164. Cell Culture Company
  • 165. Cell Medica
  • 166. Cell Therapies
  • 167. Celladon
  • 168. Cellectis
  • 169. CEllforCure
  • 170. CellGenix
  • 171. Cellin Technologies
  • 172. Celltrion
  • 173. Cellular Biomedicine Group
  • 174. Cellular Therapeutics
  • 175. Celonic
  • 176. Celsis (Acquired by Charles River Laboratories)
  • 177. Cenexi
  • 178. Centaur Biopharmaceutical
  • 179. Center for Molecular Medicine Cologne (CMMC)
  • 180. Centers for Disease Control and Prevention (CDC)
  • 181. Centre for Process Innovation (CPI)
  • 182. Coalition for Epidemic Preparedness Innovations (CEPI)
  • 183. Commercial & External Partnership, Industrial Affairs (CEPiA)
  • 184. Cerbios-Pharma
  • 185. Cerium Pharmaceuticals
  • 186. CEVEC Pharmaceuticals
  • 187. Charles River
  • 188. ChemPartner
  • 189. Chime Biologics
  • 190. China Regenerative Medicine International (CRMI)
  • 191. Chinese Peptide
  • 192. Chiome Bioscience
  • 193. CiMaas
  • 194. CiRA Foundation
  • 195. Citryll
  • 196. California Milk Advisory Board (CMAB)
  • 197. CMC Biologics
  • 198. CMIC
  • 199. Cobra Biologics (Acquired by Cognate BioServices)
  • 200. Cochin Shipyard (CSL)
  • 201. Cognate BioServices
  • 202. Coherus BioSciences
  • 203. Coldstream Laboratories
  • 204. Columbia University
  • 205. CombiGene
  • 206. Contract Manufacturing and Development
  • 207. Cook MyoSite
  • 208. CordenPharma
  • 209. Coretherapix (Acquired by TiGenix)
  • 210. CPC Scientific
  • 211. CRC for Cell Therapy Manufacturing Cooperative Research Center (CTM CRC)
  • 212. Creative Biolabs
  • 213. CRISPR Therapeutics
  • 214. Cryoport
  • 215. CSBio
  • 216. CureCell
  • 217. Cynata Therapeutics
  • 218. Cytiva
  • 219. CytoDyn
  • 220. CytoSen Therapeutics (Acquired by Kiadis)
  • 221. Cytovance Biologics (Acquired by Hepalink USA)
  • 222. CyTuVax
  • 223. Daiichi Sankyo
  • 224. Dalton Partners
  • 225. Dalton Pharma Services (Acquired by Seikagaku)
  • 226. DanDrit Biotech
  • 227. DaTaMabs
  • 228. DCPrime
  • 229. Denali Therapeutics
  • 230. Dendreon
  • 231. US Department of Defense
  • 232. DiNAQOR
  • 233. Disposable-Lab (Acquired by Amatsi)
  • 234. DM Bio
  • 235. Drugs for Neglected Diseases Initiative (DNDi)Downing
  • 236. Dyadic International
  • 237. Dyax (Acquired by Shire)
  • 238. Educell
  • 239. EirGenix
  • 240. Eisai
  • 241. Elion Labs (Acquired by KBI)
  • 242. Emergent BioSolutions
  • 243. Emerson
  • 244. European Regional Development Fund (EDRF)
  • 245. Enleofen Bio
  • 246. Enzene
  • 247. Epitopoietic Research (ERC)
  • 248. Esco Aster
  • 249. Etinpro (Beijing)
  • 250. EuBiologics
  • 251. Eucodis Bioscience
  • 252. EUFETS
  • 253. Eurofins Scientific
  • 254. Eurogentec
  • 255. Euticals
  • 256. EVER Pharma
  • 257. ExCellThera
  • 258. Exelead
  • 259. Exelixis
  • 260. FairJourney Biologics
  • 261. Faron Pharmaceuticals
  • 262. Federal Ministry of Education and Research (BMBF)
  • 263. FinVector
  • 264. FloDesign Sonics
  • 265. Florida Biologix
  • 266. For-Robin
  • 267. Forty Seven
  • 268. Forum for Innovative Regenerative Medicine (FIRM)
  • 269. Fred Hutchinson Cancer Research Center
  • 270. Frederick National Laboratory
  • 271. Freeline
  • 272. FUJIFILM Diosynth Biotechnologies
  • 273. Fusion Antibodies
  • 274. Gadea Pharmaceutical (Acquired by AMRI)
  • 275. Gallant Custom Laboratories
  • 276. GC Cell (Previously known as Green Cross Cell)
  • 277. GE Healthcare
  • 278. GeneCure Biotechnologies
  • 279. GeneDesign
  • 280. Genentech
  • 281. Geneos Therapeutics
  • 282. GeneScience Pharmaceuticals (Acquired by Changchun Hi-Tech Technology)
  • 283. Gene-to-Proteins (GTP) Technology
  • 284. GenIbet
  • 285. Genome
  • 286. Genopis
  • 287. Genprex
  • 288. German Center for Infection Research (DZIF)
  • 289. GigaGen
  • 290. Gilead Sciences
  • 291. GlycoSeLect
  • 292. Glycotope
  • 293. Goodwin Biotechnology
  • 294. Government of Canada
  • 295. Government of Europe
  • 296. Department for Business Energy and Industrial Strategy (BEIS)
  • 297. GP Pharm
  • 298. Grand River Aseptic Manufacturing (Acquired by Arlington Capital Partners)
  • 299. Green Cross LabCell
  • 300. GreenPak Biotech
  • 301. Greffex
  • 302. Grenoble Alpes University Hospital Griffith University
  • 303. GlaxoSmithKline (GSK)
  • 304. GTP Technology
  • 305. Gubra
  • 306. HIG Capital
  • 307. HALIX
  • 308. Hansa Biopharma
  • 309. Harbin Hou pu Tong tang Biotechnology
  • 310. Harbour BioMed
  • 311. Harpoon Therapeutics
  • 312. Heidelberg Pharma
  • 313. Hemogenyx Pharmaceuticals
  • 314. Hepalink USA
  • 315. Histocell (Acquired by Noray)
  • 316. Minaris Regenerative Medicine (Previously known as Hitachi Chemical Advanced Therapeutics Solutions (HCATS)
  • 317. Hong Kong Institute of Biotechnology
  • 318. Hookipa Biotech
  • 319. Horizon Therapeutics
  • 320. Hospira (Acquired by Pfizer)
  • 321. Houston Methodist
  • 322. Humanigen
  • 323. Hummingbird Bioscience
  • 324. Hybio Pharmaceutical
  • 325. Hycult Biotech
  • 326. Hygeia Health
  • 327. International AIDS Vaccine Initiative (IAVI)
  • 328. IBC Generium
  • 329. IBI Lorenzini
  • 330. Icagen
  • 331. Ichnos Sciences
  • 332. ID Pharma
  • 333. IDT Biologika
  • 334. I-Mab
  • 335. Immune Pharmaceuticals
  • 336. ImmunoCellular Therapeutics
  • 337. Immunocore
  • 338. ImmunoGenesis
  • 339. ImmunoTek Bio Centers
  • 340. Imperial Innovations
  • 341. In3Bio
  • 342. IncoCell Tianjin (A subsidiary of Boyalife)
  • 343. Indapta Therapeutics
  • 344. Industrial Strategy Challenge Fund (ISCF)
  • 345. Inhibrx
  • 346. Inno Biologics
  • 347. Innovate UK
  • 348. Innovation Network Corporation of Japan (INCJ)
  • 349. Inovio Pharmaceuticals
  • 350. Israel Institute for Biological Research (IIBR)
  • 351. Institute for Research
  • 352. INSERM-ANRS
  • 353. Integrated DNA Technologies (IDT)
  • 354. Integrity Biosolution (Acquired by Symyx Technologies)
  • 355. IntellectiveBio
  • 356. International Consortium of Investigative Journalists (ICIJ)
  • 357. International Finance Corporation (IFC)
  • 358. Intervacc
  • 359. Invetech
  • 360. Iovance Biotherapeutics
  • 361. IQVIA
  • 362. Irvine Scientific
  • 363. IsoPlexis
  • 364. Istituto Biochimico Italiano Giovanni Lorenzini
  • 365. IVERIC bio
  • 366. Janssen Pharmaceuticals
  • 367. Japan Tissue Engineering
  • 368. Japanese Society for Regenerative Medicine
  • 369. JHL Biotech
  • 370. Jiangsu Hengrui Medicine
  • 371. Jianyi Biotechnology
  • 372. Jitsubo (Acquired by Sosei)
  • 373. Johns Hopkins University School of Medicine
  • 374. Johnson & Johnson
  • 375. JOINN Biologics
  • 376. JSR
  • 377. Jubilant HollisterStier
  • 378. Juniper Pharmaceuticals
  • 379. Juno Therapeutics
  • 380. Junshi Biosciences
  • 381. Just - Evotec Biologics
  • 382. KABS Pharmaceutical Services
  • 383. Kamat Pharmatech
  • 384. Kanaph Therapeutics
  • 385. Kanda BioTech
  • 386. Kaneka Eurogentec
  • 387. KBI Biopharma
  • 388. Kemwell BioPharma
  • 389. Kiadis Pharma
  • 390. Kite Pharma
  • 391. Kodiak Sciences
  • 392. KriSan Biotech
  • 393. KUBio
  • 394. LamKap Bio
  • 395. LAMPIRE Biological Laboratories
  • 396. Lava Therapeutics
  • 397. Leanbio
  • 398. LEUKOCARE
  • 399. Levena Biopharma
  • 400. LFB Biomanufacturing
  • 401. LNC Therapeutics
  • 402. Lonza
  • 403. LSNE Contract Manufacturing
  • 404. LucasPye BIO
  • 405. Luina Bio (Previously known as PharmaSynth)
  • 406. Lyophilization Technology
  • 407. Lyophilization Services of New England (LSNE)
  • 408. Lysogene
  • 409. MabPlex
  • 410. MAbSilico
  • 411. Mab-Venture Biopharma
  • 412. MacroGenics
  • 413. Maine Biotechnology (Acquired by BBI )
  • 414. Massachusetts Eye and Ear
  • 415. MassBiologics
  • 416. MaSTherCell
  • 417. Matica Biotechnology
  • 418. Maven Capital Partners
  • 419. Medeor Therapeutics
  • 420. Medigene
  • 421. MedImmune
  • 422. MEDINET
  • 423. Medisuns
  • 424. Medix Biochemica
  • 425. MEMO Therapeutics
  • 426. Menarini Biotech
  • 427. Merck
  • 428. Merck Millipore
  • 429. Meridian Life Science
  • 430. Mesoblast
  • 431. MicroBiopharm Japan
  • 432. MicrofluidX
  • 433. Mila's Miracle Foundation
  • 434. Milner Therapeutics Institute
  • 435. Minneapolis Medical Research Foundation (MMRF)
  • 436. Mitsubishi Gas Chemical
  • 437. Mitsubishi Tanabe Pharma
  • 438. Moderna
  • 439. Molecular Partners
  • 440. MolMed (Acquired by AGC Biologics)
  • 441. Morphotek
  • 442. Merck Sharp & Dohme (MSD)
  • 443. MTI-GlobalStem (Acquired by Thermo Fisher Scientific)
  • 444. Multispan
  • 445. Mycenax
  • 446. Najít Technologies
  • 447. Naobios
  • 448. National Cancer Institute
  • 449. National Center for Advancing Translational Sciences (NCATS)
  • 450. National Heart, Lung, and Blood Institute (NHLBI)
  • 451. National Institute of Allergy and Infectious Disease (NIAID)
  • 452. Nature Technology
  • 453. Navrogen
  • 454. Neovacs
  • 455. NeoVentures Biotechnology
  • 456. Neuland Health Sciences
  • 457. NeuroFx
  • 458. Neuway Pharma
  • 459. Nikon CeLL innovation
  • 460. Nitto Avecia Pharma Services
  • 461. Nitto Denko Avecia
  • 462. Northway BiotechPharma
  • 463. Nouscom
  • 464. Novartis
  • 465. Novasep
  • 466. Novavax
  • 467. Novex Innovations
  • 468. Numab Therapeutics
  • 469. NYU Langone Health
  • 470. OBI Pharma
  • 471. Octane Biotech
  • 472. Ocugen
  • 473. Odylia
  • 474. Ology Bioservices
  • 475. Olon
  • 476. Omeros
  • 477. Omnia Biologics
  • 478. OncoQuest
  • 479. OncoVent
  • 480. Ondek
  • 481. Ono Pharmaceutical
  • 482. Orchard
  • 483. Orgenesis
  • 484. ORPEGEN Peptide Chemicals
  • 485. Osaka University
  • 486. OSE Immunotherapeutics
  • 487. OsoBio (Acquired by AMRI)
  • 488. Otsuka Pharmaceutical
  • 489. Oxford Biomedica
  • 490. Oxford Genetics
  • 491. Oxford MEStar
  • 492. PacificGMP (Acquired by Abzena)
  • 493. PaizaBio
  • 494. Pall Corporation
  • 495. Panacea Biotec
  • 496. PanCELLa
  • 497. Panolos Bioscience
  • 498. Paragon Bioservices
  • 499. Parker Institute for Cancer Immunotherapy
  • 500. Particle Sciences
  • 501. PATH
  • 502. Patheon (Acquired by Thermo Fisher Scientific)
  • 503. PaxVax
  • 504. PCI Pharma Services
  • 505. PCT
  • 506. Pfizer
  • 507. Pfizer CentreOne
  • 508. Phanes Therapeutics
  • 509. Pharma Bio
  • 510. PharmaCell
  • 511. Pharmedartis
  • 512. Pharmicell
  • 513. PHion Therapeutics
  • 514. Pierre Fabre
  • 515. Pionyr Immunotherapeutics
  • 516. Piramal Pharma Solutions
  • 517. PlasmidFactory
  • 518. Polaris Pharmaceuticals
  • 519. Polpharma Biologics
  • 520. Polymun Scientific
  • 521. PolyPeptide
  • 522. Portola Pharmaceuticals
  • 523. Porton Biopharma
  • 524. Praxis Pharmaceutical
  • 525. Precision Antibody
  • 526. Precision NanoSystems
  • 527. Prevail Therapeutics
  • 528. Immutep (Formely Known as Prima BioMed)
  • 529. PrimaPharma
  • 530. Vivoryon Therapeutics (Formely known as Probiodrug)
  • 531. ProBioGen (Acquired by Minapharm Pharmaceuticals)
  • 532. Profectus BioSciences
  • 533. Prometic Life Sciences
  • 534. Propanc Biopharma
  • 535. Proteon Therapeutics
  • 536. Provia Labs
  • 537. PTC Therapeutics
  • 538. PX'Therapeutics
  • 539. Q-Biologicals (Acquired by Amatsigroup)
  • 540. Radimmune Therapeutics
  • 541. Refana
  • 542. REGENXBIO
  • 543. Regulus Therapeutics
  • 544. Relief Therapeutics
  • 545. ReNeuron
  • 546. Rentschler Biopharma
  • 547. Rentschler Biotechnologie
  • 548. Rentschler Fill solutions
  • 549. RevaTis
  • 550. Rexgenero
  • 551. Richter-Helm BioLogics
  • 552. Ridgeway Biologicals
  • 553. River Vision Development
  • 554. Roche
  • 555. Rocket Pharmaceuticals
  • 556. Roslin Cell Therapies
  • 557. Ruibo Bio-Technology
  • 558. Saiba
  • 559. Sam Chun Dang Pharm
  • 560. Samsung BioLogics
  • 561. SanBio
  • 562. Sandoz
  • 563. Sanofi
  • 564. Sanofi-Aventis
  • 565. Sanpower
  • 566. Santen Pharmaceutical
  • 567. Sarepta Therapeutics
  • 568. Sartorius Stedim Biotech
  • 569. Scancell
  • 570. Scientific Protein Laboratories (Acquired by Shenzhen Hepalink Pharmaceutical)
  • 571. ScinoPharm
  • 572. Selecta Biosciences
  • 573. Seneca Partners
  • 574. Senn Chemicals
  • 575. Serendex Pharmaceuticals (Acquired by Savara Pharmaceuticals)
  • 576. Serum Institute of India
  • 577. Servier
  • 578. Shanghai Jiao Tong University
  • 579. Sheba Medical Center
  • 580. Shengnuo Peptide
  • 581. Shenzhen JYMed Technology
  • 582. Shenzhen Watsin Genetech
  • 583. Shire (acquired by Takeda)
  • 584. Showa Denko
  • 585. Siam Bioscience
  • 586. Siegfried
  • 587. SillaJen
  • 588. Singota Solutions
  • 589. SIRION Biotech
  • 590. Sistemic
  • 591. Sonnet BioTherapeutics
  • 592. Spicona
  • 593. ST Pharm
  • 594. Stanford University School of Medicine
  • 595. STCube
  • 596. Stelis BioSource
  • 597. Stemmatters
  • 598. Stratophase
  • 599. Sumagen
  • 600. Sumitomo Dainippon Pharma
  • 601. Sun Pharma
  • 602. Surface Oncology
  • 603. Surrozen
  • 604. Symbiosis Pharmaceutical Services
  • 605. Symphogen
  • 606. Wacker Biotech (Formely known as Wacker)
  • 607. Synklino
  • 608. Synpromics
  • 609. Synthace
  • 610. Synthelis
  • 611. Takara Bio
  • 612. Taron Solutions
  • 613. TCR2 Therapeutics
  • 614. Tectron
  • 615. Telix Pharmaceuticals
  • 616. Terumo BCT
  • 617. The Chemistry Research Solution (TCRS)
  • 618. Development Bank of Wales
  • 619. John Hopkins University
  • 620. The Michael J. Fox Foundation
  • 621. The Native Antigen Company
  • 622. Theracell Advanced Biotechnology
  • 623. Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI)
  • 624. University of Manchester
  • 625. Therapure Biopharma (Acquired by Resilience Biotechnologies)
  • 626. Theravectys
  • 627. Thermo Fisher Scientific
  • 628. Thousand Oaks Biopharmaceuticals
  • 629. TIEN (Tianjin) Pharmaceutical
  • 630. TiGenix
  • 631. Tillotts Pharma
  • 632. Tizona Therapeutics
  • 633. T-knife
  • 634. Tmunity Therapeutics
  • 635. Tonix Pharmaceuticals
  • 636. Toyobo
  • 637. TRACON Pharmaceuticals
  • 638. TrakCel
  • 639. Transgene
  • 640. Translate Bio
  • 641. Transporin
  • 642. TranXenoGen
  • 643. Trefoil Therapeutics
  • 644. Trellis Bioscience
  • 645. TRIANNI
  • 646. Trieza Therapeutics
  • 647. Trio Pharmaceuticals
  • 648. Triphase Accelerator
  • 649. Tsinghua University Innovation Center for Immunotherapy
  • 650. TUBE Biopharmaceuticals
  • 651. TxCell (Acquired by Sangamo Therapeutics)
  • 652. U.S. Department of Defense
  • 653. U.S. Government
  • 654. UGA Biopharma
  • 655. UK Cystic Fibrosis Gene Therapy Consortium (GTC)
  • 656. UK Government
  • 657. Ultragenyx Pharmaceutical
  • 658. University College London (UCL)
  • 659. University of Aberdeen
  • 660. University of Birmingham
  • 661. University of California
  • 662. University of Illinois
  • 663. University of Leeds
  • 664. University of Pennsylvania
  • 665. University of Queensland
  • 666. University of Sheffield
  • 667. University of Tokyo
  • 668. STUNS Life Science
  • 669. Vaccines Manufacturing and Innovation Centre (VMIC)
  • 670. Vaccitech
  • 671. Valerius Biopharma
  • 672. Valneva
  • 673. Vaxart
  • 674. VBi Therapeutics
  • 675. VBI Vaccines
  • 676. Vectron Biosolutions
  • 677. Vetter Pharma
  • 678. VGXI
  • 679. Vibalogics
  • 680. VIDO-InterVac
  • 681. Vigene Biosciences
  • 682. Vineti
  • 683. Virovek
  • 684. Viscofan
  • 685. Voyager Therapeutics
  • 686. Vipassana Research Institute (VRI)
  • 687. VTT Technical Research Centre of Finland
  • 688. Wacker Biotech
  • 689. Waisman Biomanufacturing
  • 690. West Biotherapy
  • 691. WIL Research
  • 692. Wistar Institute
  • 693. WuXi AppTec
  • 694. WuXi Biologics
  • 695. Wuxi Griffin
  • 696. Xbrane Biopharma
  • 697. Xellbiogene
  • 698. XL-protein
  • 699. Xpress Biologics
  • 700. Yposkesi
  • 701. Yuhan
  • 702. Zealand Pharma
  • 703. Zelluna Immunotherapy
  • 704. Zhejiang Hisun Pharmaceutical
  • 705. Zhejiang Teruisi Pharmaceutical
  • 706. Zhittya Genesis Medicine
  • 707. Ziopharm Oncology
  • 708. Zumutor Biologics
  • 709. Zymeworks